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AN EVALUATION OF CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST 
DEVICES AND THE INCIDENCE OF STROKE IN PATIENTS AWAITING 
HEART TRANSPLANTATION  
DOUGLAS-JARRETT COLE TURNO  
ABSTRACT 
 Continuous-flow left ventricular assist devices provide mechanical circulatory 
assistance for patients suffering from end-stage heart failure that are awaiting or 
ineligible for heart transplantation. Although actuarial survival and quality of life with 
these devices is comparable to allograft transplant, they are associated with severe 
adverse events, including cerebrovascular accidents. Recent advances in continuous-flow 
technology aim to mitigate the risk of stroke by including design features that minimize 
flow stasis, turbulence and endothelial dysfunction, as well as promote near-normal pulse 
pressures. The proposed study is a multicenter, prospective, randomized clinical trial that 
aims to compare the stroke-free survival and associated incidence and risk of 
cerebrovascular accidents between three continuous-flow left ventricular assist devices in 
patients with refractory, end-stage heart failure planning to undergo bridge-to-transplant 
or destination therapy. Patients will be randomized to receive one of three devices 
(HeartMate II, Thoratec Corporation, Pleasanton, CA; HeartWare HVAD, HeartWare 
International Inc., Framingham, MA; HeartMate III, Thoratec Corporation, Pleasanton, 
CA).	Patients will be monitored for stroke-free survival and incidence of cerebrovascular 
accident for 24 months post-implantation. Investigators will compare stroke-free survival 
with Kaplan-Meier survival curves and log-rank testing; in addition, investigators will 
		 vi 
examine each device’s level of risk for causing a cerebrovascular accident with chi 
square and odds ratio analysis. The data from this study will be used to guide treatment 
paradigms, device assignment and future development of technologies that mitigate 
stroke risk in this high-risk population. 
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INTRODUCTION 
Background 
Congestive heart failure (CHF) affects nearly 6 million people over the age of 20 in this 
country. The National Heart, Lung and Blood Institute (NHLBI) estimates 870,000 cases 
are diagnosed every year. The prevalence of heart failure (HF) in the United States across 
all age groups is forecast to rise at an unprecedented rate due in part to the growing 
obesity epidemic and aging population. Patients with the severest level of disease per the 
New York Heart Association (NYHA) Functional Classification System for Heart 
Failure, tiered by degree of symptomology and functional impairment, face the direst 
outcomes. For patients classified as NYHA IIIb/IV, or end-stage heart failure (ESHF), 
medical management alone may only provide temporary benefit. Heart transplantation is 
the definitive treatment for ESHF in patients whose course is refractory to medical and 
nonsurgical management. 	 The Organ Procurement and Transplantation Network (OPTN), of the U.S. 
Department of Health and Human Services, reports 4,164 candidates currently wait on 
the list for cardiac transplant. In contrast, the OPTN notes 2,804 heart transplantations 
were performed in 2015, and only 246 transplants were completed through April 2016. 
Heart transplants are designated for those who meet strict eligibility criteria. Moreover, 
the donor pool for cardiac transplants lags behind the need for organs; the obvious 
discrepancy between supply and demand for cardiac allografts has left some ESHF 
patients wanting, and unfortunately, unlikely to receive a life-saving heart.  
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 Since the 1960s, mechanical circulatory support (MCS) devices have provided 
exogenous means of sustaining cardiac output in failing hearts. Companies have 
extensively invested into the development of ventricular assist devices (VADs), which 
are implantable mechanisms that replace native heart function. In 2001, the Randomized 
Evaluation of Mechanical Assistance for Treatment of Congestive Heart Failure 
(REMATCH) trial demonstrated that a first-generation left ventricular assist device 
(LVAD) had significant survival benefit at 2 years compared to medical therapy in ESHF 
patients ineligible for transplant. The REMATCH results beautifully illustrated the 
concept of destination therapy for this population. Destination therapy (DT) refers to the 
use of a MCS system, typically a LVAD, for long-term cardiac support for those 
ineligible for transplant. The REMATCH trial established DT as a FDA-approved 
treatment for ESHF patients contraindicated for transplantation. 
 LVADs are not without their risks; first-generation LVADs were notable for high 
rates of infection, bleeding, as well as a high likelihood for device failure necessitating 
replacement within 2 years after implantation. In addition, these initial devices 
demonstrated significant rates of cerebrovascular accidents (CVAs). The development of 
second-generation LVADs, described as continuous-flow mechanisms (CF-LVADs), 
brought about a new age in MCS technology. Second-generation LVADs utilize rotary 
pump mechanisms that provide linear blood flow at a constant pressure; these models are 
also smaller in design, more durable and have a decreased incidence of adverse events. 
However, the overall incidence of stroke was not significantly different from previous 
models. Third-generation CF-LVADs utilize centrifugal rotary systems to spin blood 
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tangentially via magnetic or hydrodynamically levitated impellers and have the potential 
for reduced risk of thrombus formation. Advanced-third generation CF-LVADs, which 
combine centrifugal rotary mechanisms based on magnetic levitation technology with 
programmed pulsatile settings, are the newest models on the VAD market. Although the 
use of CF-LVADs has demonstrated an overall reduction in adverse events, morbidity 
due to ischemic and hemorrhagic stroke remains a serious complication in this group. 
 
Statement of the Problem 
As DT becomes more prevalent for ESHF patients ineligible for transplant, CF-LVADs 
promise higher long-term functional status and overall improved quality of life. The 
success of CF-LVADs regarding device durability and survival has spurred research 
aiming to further reduce adverse outcomes, such as bleeding, thromboembolism, and 
ultimately, stroke. Multiple studies have indicated that patients with CF-LVADs have 
alterations in their coagulation and hemostatic pathways.1 Such abnormalities relate to an 
intrinsic coagulopathy secondary to the device itself, leading to hypercoagulability, 
fibrinolysis and platelet dysfunction.2 To complicate management further, CF-LVADs 
require long-term anticoagulation therapy, which predisposes patients to hemorrhage. 
Optimum anticoagulation protocols suffer inter-facility and inter-patient variability.2,3 By 
understanding the physiologic effects of rotary pump systems companies can develop 
technologies that decrease the inherent mechanical factors that place individuals at 
higher-risk for stroke.  
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Sparse data is available comparing advanced third-generation CF-LVADs to 
previous second-generation or third-generation devices, specifically in regards to rates of 
ischemic and hemorrhagic stroke.  
 
Hypothesis 
An advanced third-generation CF-LVAD, the HeartMate III (Thoratec Corporation, 
Pleasanton, CA), will have greater stroke-free survival and lower associated incidence of 
stroke compared with a second-generation (HeartMate II, Thoratec Corporation, 
Pleasanton, CA) or third-generation CF-LVAD (HeartWare HVAD, HeartWare 
International Inc., Framingham, MA).  
 
Objectives and specific aims 
Since the REMATCH trial in 2001, advances in long-term MCS technologies have 
allowed ESHF patients a higher quality of life without transplant. Destination therapy 
with CF-LVADs may supplement the increasing need for donor hearts. However, patients 
with long-term use of CF-LVADs are at elevated risk for adverse outcomes, including 
stroke. Cerebrovascular accidents in this population are associated with increased 
morbidity and mortality, and decreased likelihood of receiving a transplant.4,5 This study 
proposes to further explore the association between individual continuous-flow devices 
and stroke by comparing stroke-free survival across three device cohorts through a 
prospective randomized clinical trial.  Additional aims of this proposed study include:  
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• To determine a strength of association between each device mechanism and 
stroke 
• To compare the overall incidence of cerebrovascular accidents in three CF-LVAD 
models  
• To examine the odds ratio for stroke in three different CF-LVAD models 
• To characterize stroke type in three CF-LVAD models  
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REVIEW OF THE LITERATURE 
Overview of Mechanical Circulatory Support  
Estimates based off of population growth indicate that by the year 2030, the total number 
of CHF cases is expected to increase by 46% in the United States. By that same year, 
more than 8 million patients will be diagnosed with HF. Heart failure is most common 
amongst the elderly, and by 2050, approximately 20% of the population will be greater 
than 65 years of age.6 The total direct cost of HF will rise 3-fold over the next fifteen 
years, increasing to approximately $160 billion dollars annually, assuming a continued 
rate of inflation for medical care.7 Although treatment paradigms have improved over 
time, current overall 5-year mortality rates from the time of diagnosis approach 50%; 
moderate to severe HF patients suffer worse outcomes, with 1-year mortality rates 
remaining as high as 20-50%.6,8  
 Per the 2013 American College of Cardiology Foundation (ACCF)/American 
Heart Association (AHA) Guideline for Heart Failure Management, HF is a clinical 
syndrome caused by any disorder effecting cardiac structure or function, and hallmarked 
typically by left ventricular myocardial dysfunction.6 More common causes of HF are 
ischemic heart disease, uncontrolled hypertension and diabetes mellitus, as well as 
various cardiomyopathies, myocarditis, toxins, untreated arrhythmias or valvular 
disease.9 Physiologic compensatory processes, namely volume expansion and 
neurohormonal activation, aim to increase the rate of blood flow at the expense of 
elevated filling pressures within the heart.10 Hypertrophic factors, i.e. mechanical strain, 
angiotensin, cytokines and oxidative stress, caused or released by the compensatory 
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mechanisms lead to myocardial changes known as maladaptive compensation.11 
Ultimately, mechanical and biochemical maladaptive processes lead to pathologic cardiac 
remodeling, further decreasing cardiac function.  
 Symptoms of HF directly result from the maladaptive physiologic processes at 
play: volume expansion and neurohormonal activation.10 These processes directly affect 
fluid shifts in the intravascular space, leading to fluid retention. As a result, the patient 
may complain of dyspnea, fatigue, angina, palpitations and/or peripheral edema which 
may culminate into exercise intolerance.6,8 Since HF is a clinical diagnosis, the patient’s 
symptomology and level of function compared to baseline are critical in staging the 
severity of the disease.  
The NYHA Functional Classification System for Heart Failure was first used to 
describe symptomatic functional impairment secondary to HF in 1928. For decades, 
researchers have used this system to subjectively differentiate and track patients’ disease 
process based on functional capacity.12 The NYHA classification system can readily 
discern between mild and severe cases of HF, but does not definitively distinguish 
moderate and advanced-staged disease.12 The ACCF/AHA Stages of HF also describes 
the progression of disease, but incorporates important goals of care based on the severity 
of the patients’ HF.6 Table 1 compares the ACCF/AHA staging and NYHA classification 
system. Where the NYHA system depicts the spectrum of disease, the ACCF/AHA stages 
provide a definitive separation between potentially reversible HF and advanced HF 
requiring more invasive therapy.  
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Table 1. Comparison of ACCF/AHA Stages of Heart Failure and NYHA Functional 
Classification System for Heart Failure.  
 
ACCF/AHA Stages of Heart Failure NYHA Functional Classification System 
A -At high risk for HF, 
no structural heart 
disease or symptoms  
-Modify Risk Factors 
None --- 
B -Structural heart 
disease, w/o symptoms 
-Treat structural 
disease 
I No functional limitation; 
ordinary ADLs cause no HF 
symptoms 
C -Structural heart 
disease, w/ prior or 
current symptoms 
-Reduce morbidity and 
mortality 
I No functional limitation; 
ordinary ADLs cause no HF 
symptoms 
II Slight functional limitation; 
comfortable at rest; ADLs cause 
symptoms of HF 
IIIa/b Marked functional limitation; 
comfortable at rest; ADLs cause 
symptoms of HF 
IV Severe functional limitation; 
symptoms occur at rest  
D -Refractory HF 
-Invasive interventions 
to reduce morbidity 
and mortality 
IV Severe functional limitation; HF 
symptoms occur at rest  
ACCF (American College of Cardiology Foundation); AHA (American Heart 
Association); ADL (activities of daily living); HF (heart failure); IIIa/b (continuum of 
disease, with ‘b’ representing more severe HF); Adapted from Yancy CW, Jessup M, 
Bozkurt B, et al. 2013  
 
 Medical management in HF begins by identifying patients with critical risk 
factors: hypertension, diabetes mellitus, metabolic syndrome and atherosclerotic disease. 
Patients with ACCF/AHA Stage A or B disease will receive a wide range of medications 
that target these predisposing factors. Angiotensin converting enzyme inhibitors (ACEIs), 
angiotensin receptor blockers (ARBs), statins and beta blockers, as well as satisfactory 
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glycemic control are recommended for mild to moderate HF. Serial evaluations of 
volume status – weight, jugular venous pressure, and peripheral edema – as well as serial 
echocardiographic imaging assess and plot cardiac function. As patients suffer worsening 
HF, Stage C disease or NYHA II-III, they may require an implantable cardiac 
defibrillator (ICD), stringent diet and sodium restriction, diuretics, nitrates and/or 
aldosterone antagonists to maintain desired blood pressures. In addition, patients with 
comorbid arrhythmias or ischemic disease may require some combination of 
revascularization, antithrombotic therapy, anti-arrhythmic medication, 
pacemaker/defibrillator implantation, or cardioversion.6  
 Stage D HF describes patients with advanced or end-stage disease whose course 
may be refractory to previous medical and invasive management. Patients may exhibit 
NYHA III or IV symptoms, have reduced ejection fraction (EF) below 30%, elevated 
pulmonary capillary wedge pressures (PCWP), and severely impaired functional capacity 
with multiple hospitalizations within 6 months.6 Appendix I contains a complete 
definition of advanced heart failure. ESHF patients may be candidates for specialized 
treatments, including continuous IV inotropic support, short or long-term MCS or cardiac 
transplantation. Heart transplant is considered the definitive, gold standard treatment for 
ESHF, capable of reversing the progression of disease.6,13  
 It is crucial to rule out other etiologies for refractory HF, including malignancy, 
concomitant pulmonary disease, toxins, reversible ischemic disease or noncompliance 
when evaluating patients for more intensive therapies. Table 2 lists major selection 
criteria and indications for cardiac transplant.  
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Table 2. Selection Criteria for Cardiac Transplantation. 
 
Absolute Indications Relative Indications Insufficient Indications 
-Hemodynamic 
compromise  
- Refractory 
cardiogenic shock 
- Documented IV 
inotropic support 
dependence 
- Peak VO2 < 10 
ml/kg/min 
 
-Severe ischemic 
symptoms at rest not 
amendable to 
revascularization 
 
-Recurrent, refractory and 
symptomatic ventricular 
arrhythmias  
-Peak VO2 11-14 ml/kg/min 
(55% of predicted) with 
marked ADL limitation 
 
-Recurrent unstable 
ischemia not amendable to 
interventions 
 
-Recurrent fluid imbalance 
or renal dysfunction not due 
to medical non-compliance 
-Low left ventricular 
ejection fraction 
 
-History of NYHA III or 
IV symptoms alone 
 
-Peak VO2 > 15 ml/kg/min 
(greater 55% of predicted) 
in the absence of other 
indications  
ADL (activities of daily living); Peak VO2 (peak volume of oxygen); Adapted from 
Friedrich EB, Böhm M. et al., 2007  
 
Although cardiac transplant has been found to improve exercise capacity, quality of life 
and survival compared to established therapies, not every ESHF patient is a likely 
candidate for the operation.8 Patients who are greater than 70 years old, those who have 
severe systemic (i.e. neoplastic) disease or advanced comorbidities or are morbidly obese 
have poor outcomes following transplant. Untreated psychiatric disease, mental 
retardation or poor social support are also considered relative contraindications.14 
Appendix II provides a complete list of contraindications for heart transplant. Stringent 
eligibility criteria, in conjunction with a national shortage of available donor hearts, leave 
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many critically ill ESHF patients without the chance for a life-saving organ. For this 
underserved population, advances in medical technology may provide the heart they so 
desperately require.  
In 1963, the first MCS system was implanted in a post-cardiotomy cardiac shock 
patient to provide exogenous circulatory assistance.15 The era of MCS was born out of 
federal research interest in developing short and long-term cardiac assistance modalities 
that could mitigate the high death rates on the transplant list and long wait times for 
donor identification.16 By 1978, the first LVAD was used as a temporary intervention to 
prepare a patient for cardiac transplant. By the 1990s, first-generation LVADs, utilizing 
volume displacement technologies, were introduced to clinical practice. Although these 
devices improved survival in ESHF patients, they were larger, bulkier and suffered severe 
adverse events, including thrombosis and device failure.16 Current devices utilize 
variations of rotary mechanisms, which propel blood at a near-constant pressure. These 
machines are smaller and allow increased survival with less adverse events. Future 
development will focus on device durability and biocompatibility.17 Increased survival 
with these mechanisms provides promise for ESHF patients ineligible for transplant.  
MCS systems, in particular LVADs, have been designated for one of four device 
strategies: bridge-to-recovery (BTR), bridge-to-candidacy (BTC), bridge-to-transplant 
(BTT) and destination therapy (DT). Table 3 compares the goals of each treatment 
paradigm. The latter two strategies are critical to ESHF patients in the modern era of 
MCS utilization, as evidence has indicated improved survival while awaiting 
transplant.16,18  
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Table 3. Mechanical Circulatory Support (MCS) Device Strategies  
 
Device Strategy Definition Percentage (%) of Patients 
Enrolled in Strategy (2012) 
Bridge-to-Recovery  
(BTR) 
Patient requires temporary 
support; expected cardiac 
recovery; no transplant 
indicated 
1.0 
Bridge-to-Candidacy 
(BTC) 
Patient not actively listed 
for transplant. Potential for 
recovery unclear; no 
absolute contraindication 
for transplant 
33.1 
Bridge-to-Transplant 
(BTT) 
Patient actively listed for 
transplant. Will not 
survive without 
MCS/LVAD.  
21.0 
Destination Therapy  
(DT) 
Patient is ineligible for 
transplant and will not 
survive without MCS; has 
absolute contraindication 
for transplant. 
44.0  
MCS (mechanical circulatory support); LVAD (left ventricular assist device); Adapted 
from Rodriguez et al., 2013  
 
As VAD technology has improved, the goals of newer devices are to mitigate 
adverse events and readmission rates, while sustaining patients for longer-durations.19 As 
of 2012, amongst ESHF patients ineligible for transplant, DT is the most common device 
strategy and is employed in 44% of patients requiring LVAD placement.17 Researchers 
have found that patients in DT are experiencing similar 1 and 2-year survival-rates as 
those with heart transplant.20 Implant strategies, however, are not inflexible treatment 
modalities; rather they represent modes of therapy for a spectrum of potential outcomes 
based on patient characteristics, severity of HF and likelihood of receiving a transplant or 
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becoming eligible for the waiting list.  In fact, nearly 30% of patients chosen for BTT 
strategy were found in one study to be on support 2 years post-implantation.21 As LVADs 
are increasingly used for long-duration, or even permanent therapy, decision for device 
strategy will have to address patients’ clinical need for circulatory support rather than 
their probability for receiving a new heart.  
Selection criteria for MCS will naturally parallel those of heart transplant. The 
authors of the 2013 International Society of Heart and Lung Transplantation (ISHLT) 
Guidelines for Mechanical Circulatory Support recommend long-term MCS for patients 
whose ventricular function is deemed unrecoverable, or who cannot be weaned from 
inotropic support but have the capacity for a meaningful recovery. Inotrope-dependent 
individuals, who are not in cardiogenic shock, represent a high-mortality group that may 
also benefit from MCS. Any ESHF patient with high risk for 1-year mortality should be 
referred for MCS or transplantation consult.22  
 The decision for LVAD implantation is multi-faceted, comprised of a patient’s 
surgical-candidacy, transplant status and potential survival benefit. Patient selection is 
critical to successful operational outcomes23; various risk stratification tools have been 
developed to classify ESHF patients according to surgical benefit. One of the most 
critical risk stratification tools relevant to MCS patient selection is the National Institute 
of Health (NIH) Interagency Registry for Mechanical Assist Devices (INTERMACS) 
Classification System. INTERMACS organizes refractory HF patients into more precise 
profiles, thereby identifying more appropriate MCS candidates.24 Table 4 illustrates the 
INTERMACS profiles and Appendix III provides more detailed descriptions.  
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Table 4. The INTERMACS Classification Profiles 
 
Profile Description/Status Time-Frame for Intervention 
1 Critical cardiogenic 
shock 
Hours 
2 Progressive decline Days to 1 week  
 
3 Stable, inotrope-
dependent 
Weeks 
4 Recurrent advanced HF, 
resting-symptoms 
Weeks to few months, if baseline function 
restored 
 
5 Exertion intolerant Weeks to months; variable urgency 
 
6 Exertion limited Months, if nutrition and activity maintained; 
variable urgency 
 
7 Advanced NYHA III Transplant or MCS may not be currently 
indicated 
 
HF (heart failure); NYHA (New York Health Association); MCS (mechanical circulatory 
support); Adapted from Mancini and Lietz, 2010 
 
 
 Patients in cardiogenic shock (INTERMACS 1) or patients with worsening ESHF 
symptomology (INTERMACS 2) are the sickest patients presenting for transplant or 
MCS consult. Due to the intense acuity of this population, assessment for transplant or 
emergent MCS implantation must be performed within hours. These patients may even 
receive an intra-aortic balloon pump or short-term MCS for days to weeks while the 
decision is made to pursue transplant or long-term LVAD therapy. A Futile Implant 
Score (Appendix IV), based off various individual characteristics and laboratory data, has 
been developed to determine beneficence of LVAD placement in high-risk operative 
patients. High-scoring patients (> 16) were found to have 1-year survival of less than 
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28%, and very-high scoring patients (>19) have 1-year survival less than 11%.23 No 
standardized protocols exist to guide elective device placement in this critically ill 
population.25 Parenteral inotrope-dependent patients whose disease process remains 
stable (INTERMACS 3) have 1-year survival outcomes of 23%, indicating necessity for 
MCS implantation, if transplant must be delayed.18,25 For INTERMACS 1-3 patients 
especially, MCS device strategies must be readily discussed given their high acuity. 
Destination therapy can be considered in those who are contraindicated for transplant, but 
bridge therapies represent more immediate treatment options for this population. 
Appendix V illustrates factors critical to the decision for MCS bridging therapy.  
 ESHF patients with NYHA IIIb/IV symptoms who are not inotrope dependent 
(INTERMACS 4-6) represent the ambulatory cohort of transplant/MCS candidates.25 
Physiologic parameters, such as cardiopulmonary stress testing and peak VO2 
measurements, identify patients needing invasive intervention. Prognostic evaluation 
tools, like the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model 
(SHFM), quantify the patient’s physiologic and clinical status.25,26,27 The individual can 
then be ranked according to disease severity, and thereby, their appropriateness for 
transplant listing or MCS management. Both tools’ analysis allows providers to estimate 
a patient’s 1 and 2-year survival with medical management, which is crucial to the 
LVAD implantation decision.28 
 Once an appropriate patient for MCS therapy is identified, the cardiac surgical 
team, in conjunction with heart transplant specialists, can move forward with LVAD 
implantation. Over the decades, various types of VADs have been developed, with 
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multiple devices available within each generational class. It is crucial to understand how 
each VAD system functions, as each is associated with particular advantages and 
disadvantages that may affect the course of therapy. In this paper, we will discuss each 
generation of VADs broadly and refer only to select models approved for BTT and/or DT 
as representatives of their respective generational class. Figure 1 on the following page 
illustrates the classifications of MCS devices through the generations. 
In 1994, the U.S. FDA approved a first-generation LVAD for BTT therapy. The 
first-generation devices, also known as pulsatile LVADs, attempted to mimic normal 
ventricular contractility using volume displacement technology.17 Pulsatile LVADs 
utilize pneumatic or electrically powered pumps designed with pusher-plate mechanisms. 
The HeartMate I (Thoratec Corporation, Pleasanton, CA), available as an implantable 
pneumatic [IP] or vented electric [VE] device, was the first to receive international 
marketing approval in the 1990s.29 An inflow conduit, attached at the apex of the heart, 
connects the left ventricle to the device pump. Sensors connected to the external control 
system regulate the pusher-plate, increasing or decreasing the rate of pulsation (volume 
displacement) in response to blood flow (i.e. higher rates at higher flows).29  
A diaphragm separates two chambers; one chamber houses the motor unit and the 
other houses blood. The motor compresses the diaphragm with the pusher-plate, causing 
increased pressure within the chamber, thereby ejecting blood through the outflow 
conduit anastomosed to the ascending aorta. Diastolic refilling is mimicked by a recoil 
property of the diaphragm. As the diaphragm re-expands, negative pressure draws blood 
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from the ventricle into the blood chamber, even in the setting of a flaccid left 
ventricle.29,30 
 
Figure	1:	Generational	Classification	of	VADs31	
	
To maintain proper motor unit functionality, a percutaneous driveline – 
containing an electric cable and air vent – leads from the device to the external controller; 
this prevents overheating and maintains atmospheric pressures within the motor chamber. 
Porcine valves ensure unidirectional flow. Biocompatible textured materials – titanium 
microspheres and polyurethane – promote deposition of natural endothelia.15 Creation of 
a so-called pseudointima decreases device thrombogenicity and eliminates need for 
important distinguishing design element of “contact” or
“noncontact” bearing design. The t rm “2nd ge eration” ro-
tary pump has largely been used to describe those continu-
ous-flow rotary pumps, typically with an “axial” blood flow
path, which have an internal rotor within the blood flow path
that is suspended by contact bearings (Fig. 2).12,14 However,
exceptions and differences in opinion to this general catego-
rization do exist.12 The designation “3rd generation” rotary
pump has generally been used to categorize continuous-flow
rotary devices with an impeller or rotor suspended in the
blood flow path using a “noncontact” bearing design. In the
majority of circumstances, this design utilizes a “centrifugal”
blood flow path and incorporates either magnetic and/or
hydrodynamic levitation of the internal impeller (Figs. 1
and 3).12,13,15-18 Impeller rotation to elicit blood flow is
achieved through magnetic coupling to the pump motor. A
3rd generation rotary pump with an axial blood flow path
andmagnetic levitation of the internal rotor also exists (Incor,
Berlin Heart GmbH, Berlin, Germany).15
Levitation systems utilized in 3rd generation rotary pumps
suspend the moving impeller within the blood field without
any mechanical contact, thus eliminating frictional wear and
reducing heat generation that would normally take place at
the contact surface with a contact bearing design. These lev-
itation forces may be achieved through magnetic or hydro-
dynamic bearing design. Magnetic forces may be passive
without the consumption of power (permanent magnet) or
active (induction of magnetic field with electricity) in de-
sign.12,13,16,17 Hydrodynamic levitation depends on fluid
forces generated by the rotating impeller to levitate the inter-
nal impeller.12,13 Pump designs can be further distinguished
by the utilization of hydrodynamic levitation only (VentrAssist;
Ventracor Ltd., Sydney, Australia), hydrodynamic levitation
working in synergy with magnetic levitation for suspension
Figure 1 Overview of the classification of left ventricular assist de-
vices by design generation. *The HVAD (HeartWare Corp.) utilizes
a combination of hydrodynamic and magnetic levitation of the in-
ternal impeller. #The DuraHeart (Terumo Corp.) utilizes a hydro-
dynamic bearing design for backup levitation in the event of failure
of the primary magnetic levitation system.
Figure 2 Schematic representation of a 2nd generation continuous-
flow rotary pump with an axial blood flow path and contact bearing
design suspending the internal rotor. Spinning of the internal rotor
is achieved by magnetic coupling between the rotor magnet and
external motor. (Figure courtesy of Dr. David Farrar, Thoratec
Corp., Pleasanton, CA.) (Color version of figure is available online at
http://www.semthorcardiovascsurg.com.)
Figure 3 Example of a 3rd generation continuous-flow rotary pump
with centrifugal design incorporating active magnetic levitation and
coupling of the internal impeller with a bearingless drive system.
(A) Schematic representation of the HeartMate III (Thoratec Corp.).
(a) The main flow path from the inflow section; (b) blood flow path
through the impeller and the backflow paths above the shroud and
between the rotor and motor; (c) outflow path. (Reprinted with
permission from Farrar et al.16) (B) Schematic representation of a
self-bearing or bearingless drive system in a 3rd generation contin-
uous-flow rotary pump. In a self-bearing system, both the drive and
levitation coils share the same stator core. (Reprinted with permis-
sion from Takatani S,12 ©2007 Blackwell Publishing Ltd.)
256 F.D. Pagani
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anticoagulation.29,30 Figure 2 provides a schematic of a pulsatile LVAD similar to the 
HeartMate I.  
 
 
Figure 2: Schematic of a Pulsatile LVAD.30  
 
In 2001, the REMATCH trial demonstrated that a first-generation LVAD had 
significant survival benefit compared to medical therapy alone, 52% vs. 25% one-year 
survival respectively, for long-term management of patients not eligible for transplant.18 
The trial indicated the clinical success of first-generation LVAD therapy outside of short-
duration support, and validated the concept of DT. The device functionally replaces the 
failing left ventricle, providing pulsatile blood flow at levels up to 12 liters per minute.32 
Researchers have shown that pulsatile LVADs unload strain from the left ventricle, 
promoting reverse remodeling and improved hemodynamics; some patients even 
recovered to NYHA I symptomology.32,33 The pseudointima created using textured 
biocompatible lining reduced anticoagulation needs.  
spheric pressure within the casing. This is accomplished by a
single percutaneous tube that combines the electric cable and
the air vent and allows for displacement of the olume of air
required for each filling of the blood sac. The tube is coated
with woven polyester that is designed to encourage skin in-
growth, anchoring the tube into the integument and decreasing
the risk of infection. The device has porcine valves, and all
of the internal surfaces are made of tex ured materials to
promote the deposition of a stable biologic lining, creating a
pseudoneointima similar to the lining of natural blood vessels
and thus eliminating the need for long-term anticoagulation.
When in auto mode, the device responds to increased left-sided
venous return by increasing the pump rate and output, similar
to the volume mode of the PVAD and IVAD.30
The XVE is implanted in a preperitoneal or intraperitoneal
pocket (Fig 3) and because of size can only provide univen-
tricular support and cannot be implanted in patients with a BSA
less that 1.5 m2.31 Frequently, patients with this device expe-
rience early satiety and can be predisposed to malnutrition as a
result.17 Experience with the XVE is in excess of 4,500 pa-
tients, and the longest duration of support is 1,854 days.32 It has
a higher maximum cardiac output than the IVAD or PVAD,
with a stroke volume of 83 mL and a maximum rate of 120
beats per minute. The system controller can be worn on a belt
or holster and powered with a portable battery pack, so this
device allows the most mobility of the first generation of
LVADs. The HeartM te XVE is the on y pulsa ile device
available for intermediate-to-chronic circulatory support that
requires no systemic anticoagulation.30
AbioMed Biventricular Support 5000
The AbioMed BVS5000 was th first extracorporeal VAD
available and is FDA approved for BTR in the setting of
potentially reversible HF.33 The BVS5000 is located external to
the patient and mounted on a pole. It is designed for short-term
use, and the typical length of support is 7 to 10 days. The pump
is a pneumatically driven, 2-chambered device that supports 1
side of the heart but can be used in tandem for biventricular
support. The pump casing is clear plastic, which permits visu-
alization of the chamber contents (Fig 4). Inflow and outflow
cannulae are transcutaneously tunneled, and unidirectional
valves direct flow to and from the pump casing.34 When the
device is being used for biventricular support, the respective
heights of the right and left devices can be adjusted to maintain
balanced flows and prevent pulmonary edema because filling is
by gravity drainage.35 AbioMed makes 3 different driver con-
soles: the BVS5000i, the BVS5000t, and the AB5000, all of
which can be used for the AbioMed BVS5000 pump in either
Fig 1. Thoratec PVAD/LVAD.
Pneumatic pressure provided
through the drive line com-
presses the blood sac and ap-
plied vacuum aids in filling of
the device. The full switch is
the sensor that indicates
when filling is complete and
triggers an ejection when the
device is set in volume mode.
(Courtesy of Thoratec Corpor-
tation.) (Color version of figure
is available online.)
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REMATCH’s landmark findings notwithstanding, pulsatile LVAD therapy was 
complicated by severe morbidity and mortality. The mechanism’s large size required 
invasive median sternotomy and sub-diaphragmatic implantation, with creation of a 
peritoneal pocket. Only large patients, with body surface area (BSA) greater than 1.5 
square meters could be implanted with the device.15 REMATCH noted patients with first-
generation LVADs were twice as likely to suffer a serious adverse event compared to 
those who underwent medical therapy alone.18 Pulsatile LVADs predisposed patients to 
higher risks of infection/sepsis, thrombus formation and hemolysis. Within the first 60 
days after implantation, patients experienced bleeding, infection and arrhythmias at rates 
of 36-48%; greater than 60 days post-implant, neurologic events, respiratory issues and 
tamponade occurred at rates of 24-31%.34 Pulsatile LVADs were also associated with an 
increased risk for CVA, with 14-47% of patients suffering a stroke.35 Additionally, first-
generation LVADs were likely to suffer catastrophic device failure, requiring potentially 
emergent replacement; most devices required reoperation between 18-24 months post-
implant.36 First-generation LVADs’ survival benefit for patients ineligible for transplant 
was in stark contrast to their high rate of associated complications. 
 
Cerebrovascular Accidents & Left Ventricular Assist Devices 
Cerebrovascular accidents exist as a persistent source of morbidity and mortality 
in the VAD patient population; pre-transplant strokes are major contraindications for 
subsequent transplant, and may predispose successful transplant recipients to worse 
outcomes.5,35 VADs represent a foreign substrate in the body, and as such represent a 
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procoagulant stimulus in the coagulation cascade. Multiple studies have been performed 
to demonstrate how VADs affect the hematologic state of the body.  
Spanier et al. conducted a study in a population using pulsatile VADs to illustrate 
how the device activates coagulation and fibrinolytic pathways. The researchers noted 
that VAD patients had elevated baseline levels of thrombin anti-thrombin complex and 
prothrombin activation peptide, two markers denoting production of thrombin and an 
overall procoagulant state. In addition, these respective markers were significantly 
elevated compared to those measured in patients with ESHF without VAD therapy. 
Furthermore, patients with an implanted VAD demonstrated significantly elevated fibrin 
degradation products and D-dimers compared to medically managed ESHF patients. 
VADs stimulate coagulation as well as secondary fibrinolysis.37  
Similar results were found in additional studies with focus on later generation 
VADs with continuous-flow mechanics. John et al. studied 21 second-generation LVAD 
recipients for changes in endothelial and coagulation function. Compared to a control, 
non-LVAD cardiac surgery population, VAD patients revealed increased serum markers 
for endothelial dysfunction (i.e. tissue factor, E-selectin) as well as increased markers for 
coagulation and fibrinolysis  (von Willebrand antigen, thrombin/antithrombin III).38 
Ultimately the studies noted, regardless of pulsatile or continuous-flow mechanics, the 
device, with associated altered fluid dynamics, lead to constant activation of the extrinsic 
coagulation cascade with subsequent rheologic changes. Spanier et al describe a 
compensated coagulopathy that supports thrombosis via sustained endothelial 
dysfunction.37,38 Abnormalities in endothelia and hemostasis lead to increased 
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inflammation, molecule aggregation and adhesion, all processes common to potentially 
embolic disease.38  
Transcranial Doppler (TCD) is a noninvasive test that uses ultrasound of the basal 
cerebral arteries, particularly the middle cerebral artery, to accurately visualize emboli 
traveling into the cerebral vasculature.39 High intensity signals (HITs), also known as 
microembolic signals (MES), are dynamic changes in flow velocity that are typically 
transient, unidirectional and short in duration. Figure 3 illustrates a MES waveform 
suggestive of embolus. VADs represent an obvious source for cardiac emboli.  Studies on 
prosthetic valves and structural heart disease have noted that patients with a known 
cardiac source have higher levels of MES than patients who do not, and this may predict 
higher risks for recurrent stroke, transient ischemic attacks (TIAs) or mortality.39  
 
  
Figure 3: Illustration of a Microembolic Signal (MES)39  
 
accurate, ismore indicative of its nature, andMES
will be used throughout this article to refer to
these signals.
Limitations of TCD ultrasound relate to the
difficulty of beaming ultrasound waves through
the skull, requiring lower frequency probes
than those used in carotid Duplex and diminish-
ing the ability to generate a high-quality anatomic
image. In many patients, especially in older
women, many of the vessels cannot be visualized
at all because of skull thickness and calcification.
The ability to accurately insonate vessels is a
practiced skill with the acquisition of data
being highly operator dependent and its interpre-
tation requiring considerable experience and ex-
pertise.
Of course, important in the use of TCD as a
noninvasive procedure is documenting its safety
as a monitoring tool. Some evidence has been
provided that extended monitoring of the MCA
under typical conditions and with typical settings
is indeed safe.3 MES seem to occur randomly
throughout the day without a particular circadian
rhythm identified.4Gaps betweenMES in patients
monitored long term were as high as 1 hour in
that study. The sampling period required to gain
the highest prevalence rates depend on the fre-
quency of the embolization but is believed to
require at minimum 1 hour (to compensate for
the gaps without MES) and if feasible, 2 or 4
hours (possibly on separate occasions).4,5 The
ideal length of time to monitor for emboli would
have to be some balance between efficiency
and costs involved. Most studies published on
MES detected by TCD generally record signals for
30 to 60 minutes, this appearing to be a practical
compromise.
Technical Considerations
Emboli and Artifacts
MES have particular characteristics that distin-
guish them from the waveform, background, and
artifacts that move across the monitoring screen.
They are typically short-duration HITS with a
characteristic chirping sound,which are unidirec-
tional and occur randomly within the cardiac
cycle. The first time one is heard and seen, it
appears quite striking. Despite the obvious nature
of the MES, its definition has proved more elusive
than was initially imagined.
The main difficulty in emboli detection with
TCD is the ability to differentiate an embolus
from an artifact. Numerous reports have settled
on different aspects of signal characteristics. They
include signal duration, decibel level (signal inten-
sity) as comparedwith background, directionality
(either with or against the flow of blood), sound
quality, and sequential identification. An in vitro
model showed that the size of particulate em-
boli could be differentiated based on signal dura-
tion, with larger particles having a longer
duration signal.6,7 This seems a simple enough
Fig 1. Waveform generated by TCD examination f the distal MCA in a patient with proximal MCAstenosis and acute
stroke. Above the 0 line is antegrade flow in the MCA. One complex MES can be seen. It is characterized by the
essential features of an MES: unidirectional (mainly so), short duration, and transient signal, with intensity well
above the background level (seen as black here), occurring randomly within the cardiac cycle. On audio it was
associated with a characteristic ‘‘chirp.’’
MARK GORMAN136
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Data regarding VADs, microembolism and clinically significant neurologic 
events is variable. In former pulsatile models, one study noted early TCD findings of 
significantly elevated MES detections on days with clinically-evident embolic events 
compared to days without events.40 A study of 23 patients implanted with a continuous, 
axial-flow LVAD noted 10 clinically evident thromboembolic complications in 34.8% of 
patients, while overall MESs were detected in 87% of subjects.41 In this study, 
researchers found no statistical association between MES activity and the 
thromboembolic events. Regardless of pulsatile or continuous-flow mechanics, LVADs 
promote a hypercoaguable state and their effect on fluid dynamics plays a role in the 
generation of microemboli.40,41  
The incidence of stroke in the LVAD population is difficult to assess given 
variable patient and device characteristics, antithrombotic medication status and 
compliance. In one study of 230 patients implanted with a second-generation CF-LVAD, 
the overall incidence of stroke was 17%.2 In separate studies, authors report an overall 
stroke incidence in continuous-flow devices ranging 10 – 18%, with some studies 
indicating this could be as high as 25%.4,42 Ischemic strokes may occur due in part to 
deposition of fibrin or protein throughout the device, closure of the aortic valve and 
increased length of the inflow/outflow grafts.5,43 A patient history of previous CVAs, 
heart failure, atrial fibrillation and arrhythmias, diabetes mellitus, as well as increased 
duration of intraoperative aortic-cross clamping and increased duration of VAD support 
all stand as major risk factors for stroke.5,42,44 In the largest study of 956 patients for pre-
operative risk factors for stroke in patients receiving a CF-LVAD, ischemic strokes were 
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more likely when patients exhibited higher platelet counts, lower international 
normalized ratio (INR), lower partial thromboplastin time and lower Model for End-
Stage Liver Disease (MELD) score.45  
An important risk factor for stroke in LVAD patients that deserves special 
mention is infection. In CF-LVAD patients, pneumonia, sepsis and percutaneous site 
infections of the driveline are the most common infectious etiologies. A persistent 
bacteremia lasting more than 72 hours is a critical factor in predisposing patients to 
CVA.46 Staphylcoccus and Pseudomonas species are the most likely infectious 
organisms. Both species produce biofilms that adhere to the driveline and device itself, 
spreading deeper into the machine and surrounding tissues, potentially forming an 
abscess.46 Ultimately, infection exacerbates the already taxed inflammatory state of the 
VAD patient. Platelet activation, further endothelial dysfunction, systemic inflammation 
and even septic embolic seeding of the brain can occur. In one study, post-operative 
infection was the single independent risk factor for neurologic complications and CVA, 
with an odds ratio of 4.24.4 
Hemorrhagic CVAs are devastating neurologic complications in the VAD 
population. The overall incidence of hemorrhagic events is variable, occurring at a 
similar or decreased rate as ischemic strokes. The etiology for hemorrhagic CVAs in CF-
LVADs is multifactorial: fibrinolysis, acquired hematologic deficiencies and use of 
antithrombotic therapy all heighten the risk of intracranial bleeding. As noted previously, 
studies have elucidated that CF-LVAD recipients have increased fibrin degradation 
products in circulation at baseline; this is likely due to an over activated coagulation 
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cascade and the body’s attempt to break down the increased thrombosis. In addition, 
fibrinolysis can be attributed to the high shear stress on blood product due to the moving 
rotors of the device. Resultant hemolysis increases fibrinolysis and contributes to 
thrombocytopenia.47  
The major risk factors for hemorrhagic stroke are systemic infection and 
supratherapeutic INRs.5 Endocarditis and mycotic aneurysms secondary to Pseudomonas 
infection have been implicated in hemorrhagic CVAs.5,46 Elevated INRs are not always 
predictive of intracranial bleeding, as patients can have hemorrhages even when INRs are 
normal. Additional factors, such as hemostatic abnormalities and reduced pulsatility, may 
cause bleeds. CF-LVADs’ known association with endothelial dysfunction may play a 
role in both ischemic and hemorrhagic strokes.5 Hemorrhagic conversion of ischemic 
strokes is likely to occur in patients with cardioembolic sources as well as large infarction 
size.5   
High shear forces caused by the spinning rotors in CF-LVADs also lead to an 
acquired von Willebrand’s factor deficiency, similar in pathophysiology to Heyde’s 
syndrome in aortic stenosis.47,48  Acquired von Willebrand’s Syndrome (AvWS) is caused 
by a loss of larger von Willebrand factor (vWF) monomers secondary to structural 
changes in the multimer.48 These multimers play a critical role in primary hemostasis by 
binding to glycoprotein receptors.49 Patients are thereby susceptible to bleeding, 
especially gastrointestinal bleeds. Interestingly, researchers found that AvWS is 
reversible, with multimers returning to normal size and function with removal of the 
VAD.48 AvWS was first noted in axial-flow devices, but was later identified to occur in 
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centrifugal-flow devices as well.49 AvWS has not been proven to directly cause cerebral 
hemorrhagic events in the VAD population, but the syndrome complicates antithrombotic 
therapy.  
Antithrombotic regimens for CF-LVAD patients are necessary due to the fact that 
all foreign, implanted substances, regardless of biocompatibility, are not fully 
biologically inert. Therefore, blood-thinning medications are prescribed to mitigate 
thromboembolism and hemolysis.50 All therapies include a vitamin K antagonist (i.e. 
warfarin) and an antiplatelet medication (i.e. aspirin). Additional antiplatelet therapy with 
dipyridamole or clodipogrel, may be necessary if there is significant hemolysis to reduce 
platelet aggregation.50 Table 5 lists antithrombotic therapies with goal INRs for several 
VAD models. 
Table 5.  FDA Approved Ventricular Assist Device Antithrombotic Therapies 
 
Ventricular Assist Device Aspirin  Dipyridamole Vitamin K 
Antagonist 
Goal INR 
Heartmate XVE 
 
81 mg 
daily 
--- --- --- 
HeartMate II 81 mg 
daily 
75 mg BID Warfarin 1.5 – 2.0 
2.0 – 2.5  
2.5 – 3.0 
HeartWare HVAD 
 
325 mg 
daily 
--- Warfarin 2.5 – 3.0  
HeartMate III 100 mg 
daily 
--- Warfarin 2.0 – 3.0  
Adapted from Von Ruden et al., 2012, Netuka, 2015 
 
Due to the high risk of bleeding in CF-LVADs, which occurs in up to 50% of 
patients, studies have been performed to observe the effects of less aggressive 
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antithrombotic therapy.51 Boyle et al. found in a study of 331 patients implanted with a 
second-generation LVAD that thromboembolic events were more likely when INR was 
less than 1.5, while hemorrhage was more likely if INR was greater than 2.5.52 Further, 
these researchers noted infrequent thromboembolic events at INRs greater than 1.5, and 
suggested that in patients prone to bleeding, a less aggressive goal INR was appropriate.52 
Katz et al. noted a 6% overall incidence of thromboembolic events with less aggressive 
antithrombotic therapy.53 Due to a growing body of evidence for the existence of AvWS 
in CF-LVAD patients, antithrombotic therapies are not standardized. Antithrombotic 
regimens are titrated based on an individual’s risk for thromboembolism or hemorrhage, 
surgeon’s preference and manufacturer suggestions.50  
 
Second Generation CF-LVAD: HeartMate II 
The development of continuous-flow devices (CF-LVADs) provided answers to a 
multitude of problems presented by the pulsatile mechanisms. Due to the importance of 
increasing device durability, manufacturers aimed to reduce the number of moving parts 
within an LVAD system; companies focused on rotary pump designs with a single 
moving part. Second-generation devices, also known as axial flow CF-LVADs, utilize an 
internal rotor pump suspended within the blood pathway; blood-immersed bearings hold 
the pump in place. CF-LVADs eliminated the multi-chamber design and use of valves to 
reduce sites of thrombus formation. Single pump, direct-contact design (i.e. the pump is 
actively exposed to blood) minimizes device wear-and-tear. Like the first-generation 
pumps, an inflow conduit leads from the apex of the left ventricle into the device, with an 
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outflow graft anastomosed to the ascending aorta.17 Figure 4 provides an illustration of 
the HeartMate II (Thoratec Corporation, Pleasanton, CA), a second-generation LVAD. 
An external control device, connected via a driveline, responds to changing physiologic 
demands by adjusting motor speed to maintain optimal flow.  The impeller continuously 
rotates typically at 8,000-12,000 rpm, and up to 15,000 rpm, creating a near-constant 
pressure that moves blood from the ventricle through the aorta at a rate of 3-10 liters per 
minute.16,17,29 The HeartMate II also implements the use of textured biocompatible 
material to create a pseudointima on blood-contacting surfaces.  
 
 
Figure 4: Diagram of the HeartMate II – A Second-Generation Axial Continuous-
Flow LVAD.30 
 
The HeartMate II is implanted similarly to first-generation LVADs, placed in a sub-
diaphragmatic position within a surgically created peritoneal pocket; second-generation 
models, however, are much smaller than pulsatile LVADs, allowing patients with a BSA 
its size; the pump measures 2.5! 5.5 cm and weighs only 90 g,
allowing for its implantation in smaller individuals including
pediatric patients. Its size also allows for implantation either by
the routine median sternotomy approach or by left thoracot-
omy, with or without the use of cardiopulmonary bypass.58 The
pump housing resides completely within the left ventricle se-
cured with a polyester sewing ring through the ventricular wall
and a fabric graft channels flow from the pump into the aorta.
The device has successfully supported a patient for 7.5 years,
which is longer than any other type of support device available,
and to date there have been no reported mechanical failures in
the more than 200 patients with a Jarvik 2000 pump.58
The MicroMed DeBakey Axial Flow Pump
The MicroMed DeBakey ventricular assist device, now mar-
keted as the HeartAssist 5 (MicroMed Cardiovascular, Inc,
Houston, TX), is an axial flow pump that has been in devel-
opment since 1988.57 It is very similar in design to the Jarvik
2000, offering a small size of 30.5! 76 mm and 93 g. It is also
electromagnetically driven, with a spinning impeller directing
forward flow of blood. It is implanted in the pericardial space
rather than within the ventricle and has a titanium inflow
cannula and a Vascutek Gelweave vascular graft outflow conduit
(Terumo CardioVascular Systems Corp, Ann Arbor, MI) directing
flow into the ascending aorta (Fig 12). Unique to this device is an
ultrasonic flow probe placed around the outflow graft that com-
municates with the external control system. The pump can gener-
ate maximum flows of 5 L/min with a motor speed of up to 10,000
RPM.59 Because of its size, it can be used in the pediatric popu-
lation and is the only device that is FDA approved for this
indication.60 The HeartAssist 5 is currently undergoing FDA stud-
ies for its use in the adult population and is already being used for
pediatric and adult patients in Europe.61
ANESTHETIC MANAGEMENT:
PREOPERATIVE ASSESSMENT
The patient who presents for LVAD placement is typically
suffering from end-stage HF, the advanced phase of a myriad of
conditions including coronary artery disease, hypertension, valv-
ular disease, idiopathic cardiomyopathy, and congenital heart
disease.62 Whatever the cause may be, cardiac function has
deteriorated to the point that systolic and diastolic failure are
inseparable, leading to inadequate cardiac output and the po-
tential for widespread end-organ dysfunction. The surgical
candidate may have respiratory failure and be dependent on
supplemental oxygen. Patients with advanced disease may
present with pulmonary hypertension, which can be either
passive or fixed.63 Inadequate cardiac output may also lead to
renal insufficiency and hepatic dysfunction. Damage to these
organs may result in abnormal electrolytes and altered drug
pharmacokinetics,64 reflected in a decreased volume of distri-
bution and diminished clearance.65 Thus, the anesthesiologist
should expect conventional doses to produce higher-than-nor-
mal drug concentrations. Most end-stage HF patients present
with a history of prior cardiac surgery,66 blood transfusion,
and exposure to heparin. As a result, difficulties with blood
cross-matching and the presence of heparin-induced throm-
bocytopenia (HIT) may complicate the clinical scenario.
Strategies for managing the HIT-positive VAD candidate
may include the substitution of heparin with direct thrombin
inhibitors or platelet inhibitors (see the section on Choice of
Monitors and Conduct of Anesthesia for a discussion on HIT
management).
The typical LVAD candidate has poor cardiopulmonary re-
serve64-67 with elevated filling pressures. During the induction
of anesthesia, a decrease in preload may occur, leading to a
decrease in cardiac output. Conversely, preload augmentation
Fig 9. HeartMate II LVAD.
(Courtesy of the Thoratec Cor-
poration.) (Color version of fig-
ure is available online.)
Fig 10. HeartMate II Display Module. Displayed are the estimated
pump flow (in liters per minute), actual pump speed (in RPM), PI, and
pump power (in Watts). (Color version of figure is available online.)
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less than 1.5 square meters to undergo placement. Due to the device’s smaller size, the 
operation may require a median sternotomy or left thoracotomy technique.  
 Miller et al. studied the efficacy of the HeartMate II in providing circulatory 
support to patients awaiting cardiac transplant. Researchers noted that 75% of patients 
reached primary experimental end-points – successful transplantation, cardiac recovery or 
survival – at 180 days. In addition, patients supported with a second-generation CF-
LVAD had a 1-year actuarial survival of 68%.54 Similarly, Pagani et al. evaluated the 
HeartMate II for BTT indication, finding that 79% of enrolled patients received a 
transplant, underwent LVAD removal or were living with ongoing support at 18 months 
post-implant.3 Slaughter and colleagues found that the second-generation CF-LVADs had 
significantly improved actuarial survival at 2-year follow-up compared to pulsatile 
LVADs (58% vs. 24%, respectively).55 Figure 5 provides Kaplan-Meier survival curves 
comparing the HeartMate II and a pulsatile device. In addition, researchers noted 
significant reduction in the overall incidence of adverse events in patients randomized to 
the CF-LVAD group.55 The Slaughter study established HeartMate II and second-
generation CF-LVADs as viable devices for long-duration therapy, leading to FDA 
approval of the HeartMate II for DT in 2010. 
The HeartMate II is the most commonly used LVAD internationally, with 
approximately 13,000 implantations since 2000.16 The success of the axial flow CF-
LVAD model is due in part to its smaller size, simplistic design and increased durability. 
In one study analyzing 100 patients implanted with the HeartMate II, no catastrophic 
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mechanical failures were reported; 2 non-fatal malfunctions occurred, while only 1 
patient underwent device replacement due to thrombus formation.1 
 
 
Figure 5: Comparison of Kaplan-Meier Estimates of Survival Between CF-LVAD 
and Pulsatile LVAD55 
 
The HeartMate II is one of the most extensively studied CF-LVADs available; data about 
the device points to significantly improved patient hemodynamics, quality of life and 
functional capacity.55  
 Albeit the HeartMate II represented a leap forward in MCS, the second-generation 
devices are associated with new challenges. Continuous-flow models unload the left 
ventricle throughout the cardiac cycle, delivering blood systemically at reduced pulse 
pressures.56 Absence of pulsatile hemodynamics has lead to concerns about CF-LVADs’ 
effects on myocardial recovery, ventricular unloading and the adequacy of end-organ 
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and 24% (95% CI, 1 to 46%) with the pulsatile-
flow device. Eighteen of the pulsatile-flow left ven-
tricular assist devices were replaced with a con-
tinuous-flow device during the follow-up period, 
leaving only two patients with a pulsatile-f low 
device (which had been replaced) at 2 years.
Functional Status and Quality of Life
Early and sustained improvements in functional 
capacity were seen in both groups. A total of 80% 
of patients with a continuous-flow left ventricular 
assist device had NYHA functional class I or II 
symptoms at 24 months, with a doubling of the 
mean distance on the 6-minute walk test (vs. the 
distance at baseline) (Table 3). Similar trends were 
seen with quality-of-life metrics. As compared with 
the baseline scores, scores on the Minnesota Liv-
ing with Heart Failure questionnaire and the 
Kansas City Cardiomyopathy questionnaires im-
proved by over 30 points in both groups at each 
time point (except the 24-month point in the sin-
gle patient tested who had a pulsatile-flow device) 
(P<0.001).
Adverse Events
The adverse-event data are shown in Figure 3 (with 
details in the Supplementary Appendix). As com-
pared with patients with a pulsatile-flow left ven-
tricular device, there were significant reductions 
in the rates of major adverse events among pa-
tients with a continuous-flow left ventricular as-
sist device — including device-related infection 
(relating to the percutaneous lead, pump, or pump 
pocket), non–device-related infection, right heart 
failure, respiratory failure, renal failure, and car-
diac arrhythmia. The incidence of stroke did not 
differ significantly between the continuous-flow 
group (which had 0.13 events per patient-year 
[stroke in 17% of patients]) and the pulsatile-flow 
group (which had 0.22 events per patient-year 
[stroke in 14% of patients]). There was a 38% rela-
tive reduction in the rate of rehospitalization 
among patients with a continuous-flow left ven-
tricular assist device as compared with those with 
a pulsatile-flow device.
The leading causes of death among the pa-
tients with a continuous-flow left ventricular as-
sist device were hemorrhagic stroke (in 9% who 
underwent device implantation), right heart fail-
ure (in 5%), sepsis (in 4%), external power inter-
ruption (in 4%), respiratory failure (in 3%), car-
diac arrest (in 3%), and bleeding (in 3%). Among 
the patients with a pulsatile-flow left ventricular 
assist device, the leading caus s of death were 
hemorrhagic stroke (in 10% who underwent de-
vice implantation), right heart failure (in 8%), 
multisystem organ failure (in 7%), and ischemic 
stroke (in 5%).
Discussion
Our study shows that implantation of a continu-
ous-flow left ventricular assist device, as com-
pared with a pulsatile-flow device, significantly 
improved the probability of survival free of stroke 
and reoperation for device repair or replacement 
at 2 years in patients with advanced heart failure 
in whom current therapy had failed and who were 
ineligible for transplantation. In addition, the ac-
tuarial survival over a 2-year period of support by 
a left ventricular assist device was significantly 
better with the continuous-flow device than with 
the pulsatile-flow device in a population of pa-
tients whose 2-year survival rate while receiving 
medical therapy has been shown to be approxi-
mately 10%.12,13 The continuous-flow left ventric-
ular assist device was also associated with signifi-
cant reductions in the frequency of adverse events 
and the rate of repeat hospitalization, as well as 
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Figure 2. K plan–Meier Esti ates of Survival from the As-Treated Analysis, 
According to Treatment Group.
The data shown are for the 192 patients who received a left ventricular as-
sist device (LVAD). Of the 59 patients who had a pulsatile-flow LVAD, 20 
had the device replaced during the study period, with 18 (31%) receiving a 
continuous-flow LVAD instead of another pulsatile-flow LVAD. By 2 years, 
only 2 patients had a pulsatile-flow LVAD, both of whom had replacement 
devices.
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perfusion. Researchers have noted the HeartMate II has poorer myocardial recovery 
compared to pulsatile VADs, with increased levels of heart failure biomarkers, such as 
brain natriuretic peptide (BNP).56,57 Right heart failure caused by a lateral shift in the 
interventricular septum secondary to left ventricular unloading may contribute to this 
phenomenon.24 Management of CF-LVADs requires mean arterial blood pressures 
(MAP) to be maintained by vasoactive and inotropic medications, along with careful 
fluid volume control; MAP should be measured at 70-80 mmHg, and never exceed 90 
mmHg.28 Such reduced pressures, often requiring a Doppler to identify pulses, cause 
theoretical concern for end-organ hypoperfusion. However, Kamdar et al. report that 
serum creatinine and urea nitrogen levels compared between pulsatile and continuous-
flow devices do not differ significantly; hepatic function values decreased or remained 
within normal range over a three-month duration.58 The HeartMate II provides adequate 
end-organ perfusion, without detriment to end-organ function.  
Overall adverse event rates are reduced in second-generation devices compared to 
pulsatile devices, but complications associated with the HeartMate II can cause severe 
morbidity and mortality. Reduced pulse pressures have been implicated as a cause for the 
development of arteriovenous malformations and gastrointestinal bleeds; hematologic 
abnormalities, like acquired von Willebrand disease, complicate antithrombotic 
thearapy.24 One meta-analysis noted aortic valve insufficiency, due to increased afterload 
pressures in the aorta, which predispose to regurgitant flow; while decreased pulse 
pressure for prolonged durations may lead to leaflet fusion.57 Both may occur in the 
HeartMate II, leading to flow stasis and potential thrombus formation. In addition, the 
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HeartMate II is associated with embolic and hemorrhagic stroke. According to Slaughter 
et al., there was no significant difference in incidence of stroke with the HeartMate II 
compared to pulsatile models, occurring in 17% of study patients. The leading cause of 
death in the study population was hemorrhagic stroke, occurring in 9% of patients.55 The 
overall incidence of stroke in continuous-flow devices varies between 6-17%, dependent 
on variables like individual pump-characteristics, patient-related factors, and 
anticoagulation status.24 Appendix VI denotes adverse events rates from the Slaughter et 
al, 2009 trial.  
 
Third Generation CF-LVAD: HeartWare HVAD 
As survival with LVADs increases and long-duration therapy is implemented 
more frequently, research continues to reduce adverse events and improve device 
durability. Third-generation LVADs replaced axial design with centrifugal continuous-
flow mechanics, where the rotary pump is levitated using hydrodynamic or magnetic 
forces, or a combination of the two systems.16 The HeartWare HVAD (HeartWare 
International Inc., Framingham, MA) is an example of a centrifugal pump; the design 
incorporates passive magnets and hydrodynamic thrust bearings which allow the rotary 
pump to float – or levitate – in the blood pathway, minimizing the occurrence of 
prothrombotic sites.17,59 Spinning blades throw blood tangentially to produce adequate 
flow.60 As the blades spin, blood flows across the surfaces, creating lift; constant flow 
generates a cushioned space between the impeller and motor housing.59 Levitation 
technology, in theory, allows wider gaps for flow, reducing shearing forces on the blood 
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cells, while also decreasing device wear-and-tear.16 In addition, these models are smaller 
compared to axial flow devices, allowing for advances in surgical implantation 
techniques. Figure 6 depicts an illustration of the HeartWare HVAD.  
The HeartWare HVAD can be placed in an intrapericardial position, eliminating 
the peritoneal pocket and reducing surgical complications.17 The inflow conduit is 
implanted directly within the left ventricle, while the outflow graft is anastomosed to the 
ascending aorta. A subcutaneous driveline connects to an external control system, which 
regulates a fixed pump rotational speed. Centrifugal pumps produce cardiac output up to 
10 liters per minute at lower operational speeds; reduced rotational speeds of 1,800 – 
3,200 rpm allow for increased pump efficiency compared to axial designs.17,59,61  
 
 
Figure 6: Illustration of the HeartWare HVAD61 
 
available axial-flow pump, this pump has only 1 moving part.
However, this pump has no mechanical bearings, is implanted
directly in the left ventricle, and is positioned in the pericar-
dial space.
Editorial see p 3069
Clinical Perspective on p 3200
We conducted a multicenter, prospective study of this
novel, continuous-flow, centrifugal LVAD, comparing suc-
cess and survival against a contemporaneous control group
from a national registry of commercially approved ventricular
assist devices.7 We also assessed functional and quality-of-
life outcomes and adverse events in the investigational device
group.
Methods
Study Design
The study of the investigational device was conducted at 30 centers
in the United States between August 2008 and August 2010 and was
supervised by the sponsor (HeartWare) and a clinical research
organization (Novella Clinical, Durham, NC). The study was de-
signed by the sponsor’s clinical affairs group in consultation with the
Food and Drug Administration (FDA) and clinical investigators.
Coordinators at each site collected all study data electronically and
submitted them to the data analysis center of the clinical research
organization. The academic authors had independent access to the
data; they vouch for the completeness and accuracy of the data and
the analyses.
A Data Safety Monitoring Board monitored and reviewed study
compliance, adverse events, quality of life, and outcomes for the
investigational device group. A Clinical Events Committee re-
viewed, classified, and adjudicated the causes of deaths and all
adverse events of the patients who received the investigational
device on a continuous basis, supplemented with quarterly telecon-
ferences. Adverse events were classified by Interagency Registry for
Mechanical Assisted Circulatory Support (INTERMACS) criteria.7
The study was conducted in compliance with FDA regulations for
good clinical practices. The protocol was approved by the FDA and
by an institutional review board designated by each participating
clinical site.
Study Subjects
Adults with advanced heart failure who were eligible for heart
transplantation at each center and were believed to be unable to
survive without mechanical circulatory support were eligible for
enrollment in the study. For enrollment, patients had to be eligible
for United Network for Organ Sharing 1A or 1B status listing and not
be supported by any other mechanical circulatory support device
other than an intra-aortic balloon pump. (Complete inclusion and
exclusion criteria are included in the online-only Data Supplement.)
Baseline data were obtained on patient consent and enrollment
into the study. Assessments included demographics; health history;
medications; INTERMACS patient profile8 (determined by an inde-
pendent assessor); quality-of-life surveys (Kansas City Cardiomyop-
athy Questionnaire and EuroQoL EQ-5D questionnaire); 6-minute
walk test distance; hematologic, biochemical, and hemodynamic
data; and neurological and neurocognitive status.
Investigational Device
The HeartWare system consists of an implantable continuous-flow
pump with centrifugal design (HeartWare ventricular assist device
[HVAD]), an external controller, and external power sources (Figure
1). The pump is surgically placed within the pericardial space with
the integrated inflow cannula positioned in the left ventricle, avoid-
ing abdominal pump placement. The impeller, the only moving part
within the pump, is suspended by passive magnetic and hydrody-
namic thrust bearings to create contact-free rotation. The normal
operating speed of the pump is 2000 to 3000 rpm, with a maximum
flow rate of 10 L/min. The pump is connected to external system
components by a driveline that is tunneled subcutaneously and exits
the patient’s abdominal wall. A controller operates the pump,
regulates power, monitors system performance, and displays alarm
notifications. The system can be powered by the following: a pair of
rechargeable direct-current lithium-ion batteries, alternating-current
power from an electric wall outlet, or a 12-V direct-current power
source. A monitor displays pump performance, is used to set and
adjust the operating parameters, and provides a means to download
data from the controller. Details of device design, function, and
surgical implantation technique have been described previously.5,9
Follow-Up After Investigational
Device Implantation
Scheduled clinical assessments were performed until transplantation
or until 60 days beyond device explantation for recovery or until 180
days after implantation while the subject was on LVAD support.
Subjects remaining on LVAD support will be followed beyond 180
days for a total of 5 years. Assessments included physical examina-
tion, medications, functional assessments, serum chemistry and
hematology, and LVAD system management information. Neurolog-
ical assessments and quality-of-life questionnaires were adminis-
tered at week 4, months 3 and 6, annually, and at device explantation.
Anticoagulation was individualized and differed among cen-
ters. As patients tolerated oral medication, warfarin and aspirin
were started to transition from heparin (see the online-only Data
Supplement).
Control Subjects
The control group for testing the primary study hypothesis was
drawn from INTERMACS, which collects data on patients who
receive FDA-approved durable mechanical circulatory support de-
vice therapy in the United States (Figure 2 and the online-only Data
Supplement).7 The comparability of this control cohort and the
interventional group and the criteria for comparison of the outcomes
of the interventional group were determined in a prespecified manner
with the use of only baseline characteristics (see the online-only Data
Supplement).
Figure 1. Components of the HeartWare left ventricular assist
system. The continuous flow of blood through the centrifugal
pump is shown. The inflow cannula is surgically implanted into
the left ventricle. Blood is conveyed through the pump via an
impeller that is suspended by a combination of magnetic and
hydrodynamic forces, allowing frictionless rotation at operating
speeds of 1800 to 2400 rpm. Blood exits the pump into a flexi-
ble, gel-impregnated outflow cannula that is connected to the
ascending aorta by means of surgical anastomosis. The percu-
taneous lead is tunneled subcutaneously and carries wires from
the pump to an external controller. The controller regulates
power and operating signals to the pump and collects informa-
tion about operations that can be downloaded for analyses.
Two lithium ion batteries provide power with the combined
capacity of !10 hours of use. The batteries are both recharge-
able and replaceable.
3192 Circulation June 26, 2012
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Dell’Aquilla et al. and researchers initial experience with the HeartWare HVAD 
system noted similar survival curves compared to John et al.’s early findings in the 
HeartMate II (77.9% versus 78.8% overall 1-year survival).59 The ADVANCE trial 
conducted in 2012 demonstrated non-inferiority of the HeartWare HVAD for BTT device 
strategy. Researchers compared the HVAD to INTERMACS control device data, mostly 
made up of HeartMate II implantations. Investigators noted 86% 1-year survival with the 
Heartware HVAD, compared to 85% 1-year survival in the control group.61 The 
ADVANCE trial enabled FDA approval of the HeartWare HVAD for BTT, which is the 
only third-generation device approved for this indication.16 The ENDURANCE trial, an 
on-going project evaluating the HVAD for DT indication in 446 patients randomized to 
MCS support with the HVAD or HeartMate II, recently reached primary study end-
points. HeartWare International Inc. published a memorandum stating of those enrolled 
between 2010-2012, 55% experienced stroke-free survival at 2 years while supported 
with the HeartWare HVAD, compared to 57.4% who attained the same end-point with 
the HeartMate II.62 These initial results suggest non-inferiority in terms of mitigating 
stroke for the HVAD in long-term circulatory assistance for refractory ESHF patients.  
Although overall and stroke-free survival curves for the HeartWare HVAD 
suggest that the third-generation device may exist as a viable device option for ESHF 
patients, adverse events persist. A retrospective cohort study compared 46 patients 
implanted with a HeartWare HVAD or HeartMate II over a six-year timeframe noted 
similar complication rates across groups. Right ventricular failure, liver or renal 
dysfunction as well as thromboembolism, infection and bleeding occurred similarly in 
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either cohort. However, researchers noted patients with the HVAD suffered a 44% 
incidence of stroke compared to 10% in those supported with the HeartMate II, with a 
trend favoring higher incidence of hemorrhagic stroke. In addition, the same researchers 
noted a significant increase in GI bleeding with the HVAD.63 Preliminary results from the 
ENDURANCE trial noted an overall elevated risk of stroke in the newer model, likely 
due to poor blood pressure control in the investigational cohort.64,62 
 
Axial versus Centrifugal CF-LVAD Physiology 
Thrombosis results from the pathologic mechanisms of hypercoagulability, 
endothelial dysfunction and variation in hemodynamic performance, namely flow stasis 
or turbulence. VAD mechanisms contribute to each of these three processes, as a foreign 
object within the body, disrupting natural endothelia and altering fluid dynamics. As 
advanced third-generation centrifugal designs come to fruition, we can see the focus on 
LVAD development set upon decreasing hindrances to flow, producing more normalized 
pulsatile function and incorporating biocompatible materials. Although the 
bioengineering principles of VADs are outside the scope of this paper, it is crucial to 
understand basic elements of continuous flow mechanics in order to appreciate how 
advanced third-generation designs function.  
By analyzing axial versus centrifugal continuous flow mechanics, we can make 
inferences into advantages of advanced third-generation designs. Table 6 lists a summary 
of physiologic differences between the two mechanisms. The means by which VADs 
produce flow, manipulate blood and respond to physiologic demands, contributes to the 
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inherent coagulopathogenicity of the device. A device’s flow pulsatility, inlet suction 
predisposition, pre-load and after-load sensitivity, susceptibility to infection, 
biocompatibility, tendency for hemolysis and anticoagulation protocols can create an 
environment conducive for thromboembolism.  
Table 6. Summary of Physiologic Differences Between Centrifugal and Axial CF-
LVAD Designs 
 
Pump Characteristics Centrifugal vs. Axial Summary of Comparison 
Flow Pulsatility C > A Centrifugal VADs have higher 
flow pulsatility 
Inlet Suction A > C Centrifugal VADs have 
significantly lower inlet suction 
events at low flow conditions 
Pre-Load Sensitivity A = C Axial and Centrifugal VADs 
have low pre-load sensitivity, 
relative to native LV and 
pulsatile VADs 
After-Load Sensitivity C > A Centrifugal > Axial > Native 
LV/Pulsatile VADs in terms of 
after-load sensitivity 
Susceptibility to Infection A = C No difference  
Biocompatibility A = C No difference 
Hemolysis A = C Not enough clinical data to 
suggest superiority  
Anticoagulation A = C Not enough clinical data to 
suggest superiority 
A (axial); C (centrifugal); VADs (ventricular assist devices); LV (left ventricle); Adapted 
from Moazami, N et al., 2013 
 
CF-LVADs are conduits which mediate a pressure gradient between the failing 
native left ventricle and the aorta. The pressure across the inlet and outlet of these 
hydrodynamic pumps – the pressure head or delta P – illustrates the relationship between 
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pump flow and pressure at a given operating speed.60 Centrifugal systems have a flat 
pressure head curve, whereas axial designs have a steep pressure head. Centrifugal pumps 
exhibit a wide variation in operational flows over small changes in the pressure gradient, 
while axial flows do not vary significantly with changes in delta P.  
The implications of this are twofold: a) centrifugal pumps function with a higher 
degree of “pulsatility” through the cardiac cycle compared to axial devices b) centrifugal 
flows can better adapt to changing physiologic demands without causing structural 
change to the interventricular septum.60 On the following page, Figure 7 displays a visual 
schematic of the pressure heads of axial versus centrifugal machines. Inlet suction events 
occur more frequently in axial devices in low flow states, where the negative pressure 
generated by the rotor mechanism causes a leftward shift of the septum; this causes right 
heart dilatation, decreased device efficiency and may lead to other problems with device 
function.  In centrifugal designs, the relative increased pulsatility and decreased inlet 
suction events thereby lessen flow stasis and mitigate the occurrence of ventricular 
arrhythmias and right heart dysfunction, which can predispose to thrombus formation.  
Pre-load and after-load are hemodynamic conditions that contribute to overall 
cardiac output. In MCS devices, pre-load refers to the relationship between the left 
ventricular filling pressures and left ventricular stroke volume.60 Continuous flow pumps 
have a reduced internal volume, by nature of their size compared to the native ventricle, 
and therefore have a limited pre-load sensitivity. CF-LVADs have a restricted output 
response to variations in venous return, which makes maintenance of euvolemia 
challenging. However, continuous flow devices demonstrate higher after-load sensitivity 
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compared to the normal human heart. After-load in MCS refers to the pressure gradient 
between the systemic vasculature and the device’s outlet. 
 
 
Figure 7: Example Pressure Head Curves of Axial and Centrifugal Devices 
 
In order to maintain normal function of the rotor system, mean arterial pressures must be 
kept for all continuous flow devices strictly between 70-90 mmHg.22,60 Centrifugal 
devices, due to their flat head curve, are especially susceptible to deleterious effects on 
output flow in response to increased systemic vascular resistance; axial devices are less 
susceptible to after-load variation and can maintain adequate pressures due to a steeper 
delta P. Although axial devices can maintain a more constant flow to overcome increased 
vascular resistance, this predisposes to inlet suction events, arrhythmias and hemolysis, if 
venous return is not sufficient.60  
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 Hemolysis results from blood shearing effects of the rotor mechanism due to high 
rotational speed and is related to the volume of space for blood to pass through the 
device. Axial-flow VADs have smaller clearances around the rotor blades, which spin at 
higher operational speeds; this creates high shearing forces on red blood cells compared 
to centrifugal devices. Hemolysis occurs in both centrifugal and axial designs, and there 
is a lack of evidence to suggest hemolysis secondary to pump design is a major clinical 
problem in MCS devices. However, hemolysis can be the harbinger of future morbidity, 
such as outflow graft misalignment or significant thrombus formation.60 Deposition of 
fibrin clots typically occurs due to increased turbulence or stasis in “poor wash” areas, or 
sections of the device that are not exposed to adequate flow.60 Centrifugal devices like 
the advanced third-generation mechanisms, with increased clearance between the blades 
for flow, have highly washed surfaces that are protective against stasis.60,65   
 
Advanced Third Generation CF-LVAD: HeartMate III 
 A particular advanced third-generation device, the HeartMate III (Thoratec 
Corporation, Pleasanton, CA), combines successful aspects of previous generation 
design. Figure 8 illustrates the HeartMate III, a more compact centrifugal pump with a 
solely magnetically levitated rotor system; the rotation and levitation of the rotor is made 
possible by a simplistic design. A single stationary component – made up of iron poles, 
copper coils and position sensors – allows for a miniaturized mechanism that eliminates 
the need for mechanical or fluid bearings like those used in earlier VADs.16 The magnet-
based system prevents movement of the motor housing no matter what the relationship of 
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the device to the body, which decreases likelihood of device displacement. Without the 
bearings, mechanical wear-and-tear secondary to friction and device breakdown is no 
longer an issue. In addition, there are increased gaps for flow that are 10-20 times greater 
than those in hydrodynamic bearing systems, like the HeartWare HVAD.16,66 As 
previously noted, larger clearance areas for fluid movement favors laminar versus static 
flow. The system allows for high wash areas while maintaining flows between 2-10 liters 
per minute, while minimizing shear forces on blood product.16,65 Furthermore, the 
magnetic system maintains large gaps for flow to increase pump efficiency, permitting 
higher flows at lower rotational speeds between 3,000-4,000 rpm.  
 
 
Figure 8: Internal Mechanics of the HeartMate III66 
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First implantation in man of a new
magnetically levitated left ventricular
assist device (HeartMate III)
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Outcomes of heart failure patients supported by a
continuous-flow left ventricular assist device (LVAD) have
steadily improved during the past decade, largely due to
better patient selection and management.1,2 Nevertheless,
adverse events, such as bleeding, infection, stroke, and
thrombus, persist and limit the overall effectiveness of this
therapy. Bleeding is the most common serious adverse event
that results from the extensive surgery required for
implantation and blood component damage due to shear
forces in the small blood flow paths of current design axial-
flow and centrifugal-flow pumps. Excessive bleeding results
in reoperations, intensive care time, and total hospital stay,
which greatly increases a patient’s exposure for infection.
The current clinically used pumps create levels of shear
force that can activate platelets and damage von Willebrand
factor, causing a disruption in the coagulation system that
can manifest as thrombosis or gastrointestinal bleeding.
The HeartMate III LVAD (Thoratec Corp, Pleasanton,
CA) is a new compact intrapericardial centrifugal-flow pump
with a full magnetically levitated rotor (Figure 1). The design
differs from currently used devices due to actively controlled
rotation and levitation of the rotor allowing gaps in the blood
flow that are 10 to 20 times wider, which may minimize
blood component trauma and result in more stable coagula-
tion. The HeartMate III is now under clinical investigation,
and we present here a case report of the first implantation of
the device to support a patient with severe heart failure.
The patient is a 55-year-old man with the diagnosis of
dilated cardiomyopathy and a recent history of multiple
hospital admissions due to worsening heart failure symptoms.
With multiple medications, the mean arterial blood pressure
was 70 mm Hg, cardiac index was 2.1 liters/min/m2, and the
left ventricular ejection fraction was 10% to 15%.
He was classified as Interagency Registry for Mechanically
Assisted Circulatory Support Profile 3. After meeting the
HeartMate III Conformité Européene Mark Study inclusion
criteria, the patient gave informed consent, and the implanta-
tion was performed by Dr. Schmitto and his team at Hannover
Medical School, Hanover, Germany on June 25, 2014.
After a median sternotomy, the pericardium was only
partially opened to help protect right heart function
yet allowing access to the vena cava and aorta for
cardiopulmonary bypass cannulation. Once full cardiopul-
monary bypass was started, the pericardium was fully
opened, the heart was elevated, and the myocardium was
cored with the HeartMate coring knife approximately 1 cm
medial to the left ventricular apex. The sewing cuff was
attached around the apical opening with 2-0 Ethibond
pledgeted sutures. The inflow conduit was inserted into the
left ventricle, and the device was quickly secured to the heart
with a locking mechanism. The outflow graft was trimmed
for length and anastomosed to the ascending aorta. The
percutaneous lead (driveline) was externalized with a double-
tunnel technique and exited through the right upper quadrant
of the abdominal wall. Cardiopulmonary bypass lasted
59 minutes, and the total operative time was 149 minutes.
Figure 1 The Heart Mate III left ventricular assist device blood
pump with the full magne ically levit t d rotor allows large pump
gaps. Blood flow is received from the left ventricle and is pumped
through a graft attached to the ascending aorta.
1053-2498/$ - see front matter r 2015 International Society for Heart and Lung Transplantation. All rights reserved.
http://dx.doi.org/10.1016/j.healun.2015.03.001
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 The HeartMate III revolutionizes MCS design, not only for its use of magnetism, 
but also for implementing an element that harkens back to the first-generation models: 
pulsatile flow. Although the HeartMate III is classified as a CF-LVAD, the rotor 
mechanism will depart from its designated operational speed at periodic intervals, 
creating flow disruption. Regular, brief pauses in flow will act as a mechanized heartbeat, 
imitating natural cardiac contractility similar to volume-displacement technology. The 
artificial pulse may occur up to 30 times per minute, separate from the heart’s natural 
rhythm.16 During development, the artificial pulse mode was tested in sheep where the 
speed of the device fluctuated between 1,500 and 5,500 rpm at 60 beats per minute; 
researchers noted that the estimated equivalent pressure (a measure of pulsatility) rose 
significantly when pulse pressures were subsequently increased. The enhanced pulsatility 
function promotes myocardial recovery and regeneration of tissue, as well as improves 
wash area coverage to decrease thrombus formation.65 In computational fluid dynamic 
trials, researchers tested the HeartMate III at flows between 0-12 L/min to observe 
evidence of stasis or turbulence. The authors noted clean fluid dynamics over the range of 
operating speeds, while no thrombus was observed at normal or low flow conditions with 
little evidence of stasis.67  
 The HeartMate III incorporates textured titanium microspheres on all the blood-
contacting surfaces of the device, with the exception of the rotor and rotor well. Like the 
HeartMates XVE and II, this biocompatible material promotes the growth of natural 
endothelia to create a pseudoinitma.16,65 The resulting biologic lining reduces the need for 
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anticoagulation therapy. In combination with larger clearance areas due to the use of the 
magnetic-levitation system, the biocompatible material further promotes a low 
thrombogenic environment.  
 The HeartMate III is implanted adjacent to the heart in a supradiaphragmatic 
position typically via median sternotomy. The inflow conduit is placed in an 
intrapericardial position, with the outflow graft anastomosed to the ascending aorta.66,68  
 Although the HeartMate III has been studied in animal models since the early 
2000s, it was first implanted in humans in Germany in 2014. The patient was a 55-year-
old gentleman with a history of dilated cardiomyopathy and ESHF with ejection fraction 
of 10-15%. The procedure was performed without incident and the patient recovered well 
post-operatively. Nine months after implantation, the patient’s functional status had 
recovered to NYHA I disease.66  
Little clinical study data is published about the HeartMate III, but what is 
available holds promise. The HeartMate 3 CE Mark Trial was the first prospective, non-
randomized multi-center trial in humans that tested device performance and safety 
compared to the HeartMate II. Fifty patients from six European countries were implanted 
for DT or BTT between June and November 2014. The study’s primary endpoint for 
overall survival at six months was set at a performance goal of 88%, based on the 
HeartMate II. The study found the HeartMate III exceeded the performance goal, with 
92% overall survival at six months. The HeartMate III demonstrated no evidence of 
significant hemolysis, pump thrombosis or device failure necessitating pump exchange.69 
In addition, researchers noted stroke occurred in 12% of patients implanted with the 
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HeartMate III (8% ischemic, 4% hemorrhagic). The authors noted difficulties with 
intraoperative placement, infection and reaction to contrast media might have played a 
role in the incident of stroke. The trial exhibited increased survival and improved 
functional outcomes at six months with the HeartMate III, while adverse events occurred 
at similar or reduced rates than expected.69 The MOMENTUM 3 clinical trial has 
enrolled 1,028 patients since September 2014 to evaluate the HeartMate III for safety and 
effectiveness compared to the HeartMate II for ESHF.  Researchers’ primary endpoints 
include overall short and long-term survival, as well as composite survival to transplant 
or adverse event (i.e. stroke) at 6 and 24 months post-implant. Primary data collection 
will be complete in November 2018. 
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METHODS 
Study design 
The CON-FLOW STROKE clinical trial will be a multicenter, prospective, randomized 
study examining the difference in performance of three CF-LVAD devices in terms of 
stroke-free survival as well as their respective incidence and risk of cerebrovascular 
accidents.   
Study population and sampling 
The study population will be selected from 59 cardiac transplant/mechanical circulatory 
support centers in the United States (Appendix VII). Eligible candidates for this study 
will have been diagnosed with advanced heart failure, classified as NYHA IIIb (dyspnea 
with mild physical activity) or end-stage, NYHA IV disease that is refractory to medical 
management. Patients meeting inclusion criteria will be enrolled regardless of individual 
device strategy (BTT or DT).70 Appendix VIII provides a complete list of inclusion and 
exclusion criteria.70 A sample size of 291 patients per cohort, totaling a population of 873 
patients, will be enrolled in the study. Sample size will be calculated assuming a CVA 
incidence of 20% in the standard VAD population. We will aim to observe a 50% risk 
reduction in the interventional cohort, and will assume a confidence level of 95% to 
produce a study with 80% power. Patients will be considered a part of the study 
population upon signing informed consent; all consented patients will be included in the 
intent-to-treat analysis.  
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Intervention 
The proposed study will have three arms; one study arm will be randomized to 
implantation with the HeartMate II (Thoratec Corporation, Pleasanton, CA), one arm will 
receive the HeartWare HVAD (HeartWare International Inc., Framingham, MA) and the 
final treatment group will be implanted with the HeartMate III (Thoratec Corporation, 
Pleasanton, CA). Eligible candidates will be randomized 1:1:1 between the three device 
groups. Randomization will be stratified by study center and blocked to maintain a 1:1:1 
ratio over time. The randomization process will be conducted using an electronic data 
capture system (Merge Healthcare, Morrisville, NC).70 In addition, each study center will 
be limited to a maximum of 50 randomized patients to control for geographic and 
demographic differences across regions. All study patients, regardless of device, will be 
managed in accordance to the current standards of care set forth by the International 
Society for Heart and Lung Transplant Guidelines for Mechanical Circulatory Support.22  
HeartMate II 
The HeartMate II is a second generation, continuous-flow left ventricular assist device 
designed with an internal axial-flow, direct-contact blood pump. The HeartMate II is 
connected to an external power source and controller unit via a percutaneous driveline. 
The axial rotor system produces flow by spinning at 8,000 – 12,000 rpm. The device is 
implanted in a subdiaphragmatic position, within an artificially made peritoneal pocket. 
A textured biocompatible material is incorporated in the design to promote growth of 
natural endothelia. Patients will be treated with an antithrombotic regimen, consisting of 
a vitamin K antagonist and antiplatelet medications.  
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HeartWare HVAD 
The HeartWare HVAD is a third generation, continuous-flow left ventricular assist 
device designed with an internal, centrifugal blood pump that incorporates passive 
magnets and hydrodynamic thrust bearings to produce tangential flow. The HeartWare 
HVAD rotor system implements levitation technology.16 The HeartWare HVAD is 
implanted in an intrapericardial position, in contrast to the second-generation device. The 
centrifugal pump rotors spin to produce flow at 1,800 – 3,200 rpm. Patients will be 
treated with an antithrombotic regimen, consisting of a vitamin K antagonist and 
antiplatelet medications.  
HeartMate III 
The HeartMate III is an advanced third generation, continuous-flow left ventricular assist 
device designed with a more compact centrifugal pump with a solely magnetic levitated 
rotor system. The device has increased gaps for flow that are 10-20 times greater than 
those in hydrodynamic bearing systems.16,66 The rotor mechanism will depart from its 
designated operational speed at periodic intervals, creating flow disruption, acting as a 
mechanized heartbeat. The artificial pulse may occur up to 30 times per minute, separate 
from the heart’s natural rhythm.16 Flow is produced at a rotor speed of 3,000 – 4,000 rpm. 
The device is implanted in an intrapericardial position. A textured biocompatible material 
promotes growth of natural endothelia. Patients will be treated with an antithrombotic 
regimen, consisting of a vitamin K antagonist and antiplatelet medications.  
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Study variables and measures 
Study variables of interest include stroke-free survival over a 24-month, post-
implantation period. In addition, the incidence of cerebrovascular accidents – whether 
ischemic or hemorrhagic – will be documented within the same study period.  
 Stroke-free survival will be defined as the period of time post-implantation in 
which a patient is without debilitating or lethal CVA while on LVAD support. CVA will 
be defined in accordance to the INTERMACS definition: any new focal or global 
neurologic deficit ascertained by a standard neurologic examination (via a neurologist or 
qualified provider) and documented with appropriate diagnostic tests and consultation 
notes.2,71 
 Incidence of CVA will be calculated as a percentage of the total number of 
observed, new CVAs in the total study population at sequential post-implantation time 
periods: 6, 12 and 24 months.  
Recruitment 
Patients will be obtained primarily via provider referral from cardiology and cardiac 
surgery practices around the 59 cardiac transplant/mechanical circulatory support centers 
in the United States. In addition, ambulatory INTERMACS profiles 4-6 patients will be 
sent letters of notice via contact information listed with the INTERMACS national 
registry. High-risk, acute patients ranked as INTERMACS profiles 1-3 will be assessed 
for study eligibility pending clinical status by the appointed study investigator or their 
representative team at each respective center.  
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Data collection 
Data will be collected via prospective review of each center’s daily medical record in the 
immediate post-implantation period during their inpatient stay. Official neurology 
consultation notes will be reviewed for report findings from diagnostic imaging and 
testing. Upon discharge following surgery, patients will be sent home with visiting 
nursing three days per week for an additional 4 weeks, and then tapered to once weekly 
and finally, as often as the patient requires. Once discharged, CVA events will be 
monitored as they occur through visiting nurse and emergency department records. Any 
and all CVAs will be noted for date and time for each patient. In addition, CVAs will be 
documented for stroke type: ischemic or hemorrhagic. Additional data, including 
coagulation study values at the time of stroke, current antithrombotic regimen dosing and 
presence of concurrent infection will be documented. Stroke-free survival and incidence 
of CVA will be reported at 6, 12 and 24-months post-implantation.  
Data analysis 
A statistician group consulted by the clinical trial investigators will perform all data 
analysis using a statistical computing program (i.e. SPSS). Stroke-free survival will be 
calculated using log-rank tests and reported using Kaplan-Meier survival curves. In 
addition, the mean time to stroke in months will be calculated using a three-way analysis 
of variance to observe for significant difference in time across all treatment-arms. If a 
significant mean time to stroke is identified, a Tukey method will be used to further 
identify significance between one or more of the treatment arms. Chi-square and odds 
ratio analysis will be performed for incidence of stroke and to determine likelihood of 
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CVA event with each device. Correlation between each device and incidence of stroke 
will be analyzed using a Pearson’s correlation coefficient. An additional Chi-square 
analysis will be performed to characterize likelihood of CVA type – ischemic or 
hemorrhagic – in each treatment arm.  
Timeline and resources 
Personnel: 
• Study coordinator at each respective center 
• Primary investigator at each respective center 
• MCS/VAD coordinator 
• Heart Transplant/MCS clinician teams 
• Thoratec Corporation, HeartWare International Inc. representatives  
• Cardiac Surgery/Cardiac Critical Care medical and nursing specialists accustomed 
to the management needs of MCS patients 
• Neurology consulting team 
• Statistician consulting group  
Special Resources: 
• HeartMate II CF-LVADs 
• HeartWare HVAD CF-LVADs 
• HeartMate III CF-LVADs 
Timeline: see Table 7 on the following page 
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Table 7. Timeline for CON-FLOW Clinical Trial 
 
May – September 2016 - IRB proposal submitted/approved 
 
September 2016 – September 2017  - Contact and recruit study centers for 
participation 
 
- Contact ambulatory MCS patients via 
INTERMACS registry 
 
- Identification of study subjects  
 
September 2016 – September 2019 - Device implantation and monitoring  
 
- Stroke-free survival and incidence of 
CVA calculated at 6, 12 and 24 months 
post-implantation  
 
September – October 2019 - Completion of data collection period 
 
October 2019 – October 2020 - Data consolidation and analysis 
 
- Preparation and submission of 
manuscript 
 
 
Institutional Review Board 
A proposal will be submitted for IRB approval. CON-FLOW STROKE is a randomized 
clinical trial. Enrolled patients, given their general higher acuity and the nuances of MCS 
management, are subject to greater than minimal risk, and therefore this study will 
warrant full board review. 
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CONCLUSION 
Discussion 
To date, this investigator was unable to find study data comparing stroke-free survival, 
incidence and associated risk of CVA between three top-market CF-LVADs: HeartMate 
II, HeartWare HVAD and HeartMate III. Several major trials only investigated two of the 
devices in question. There have been no multicenter, prospective, randomized studies 
completed that specifically explore continuous-flow device design features and 
associated incidence and risk for CVA.  
 The proposed study is limited in regards to its ability to assess the effect of each 
device design without confounding variables. The exclusion criteria were designated to 
eliminate patients whose clinical status has a high likelihood for peri-/post-operative 
morbidity and mortality. However, patients who are eligible but categorized as 
INTERMACS profiles 1 and 2 represent a highly acute population, at higher risk for 30-
day and 1-year mortality, based on Futile Implant Scores.23 Critical patients are at 
increased risk for systemic inflammation and therefore at greater risk for a procoagulant 
state. Other confounding factors include medical non-compliance with anticoagulation 
protocols as well as concurrent infection, which may place patients at risk for CVA. 
Aortic cross-clamping times will suffer interpersonal variability based on intraoperative 
technical difficulty. As a result, patients may be at greater risk for cerebral hypoperfusion 
and CVA in the immediate post-operative period secondary to increased cross-clamp 
times and ventricular air emboli due to cardiopulmonary bypass. In addition, 
complications from the surgery may pose risk for CVA; investigators will be unable to 
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differentiate etiology of stroke due to device or procedure. Patient’s suffering high 
intraoperative blood losses necessitating multiple blood cell transfusions are at higher 
risk for stroke; investigators would be unable to differentiate the etiology of stroke 
between device or transfusion.72 Blood pressure controls would aim to maintain MAP 
between 70-80 mm Hg; patients experiencing CVA at pressures above 90 mm Hg may 
confound evidence to support CVA was caused by the device or due to hypertensive 
state.   
 The generalizability of this study will be based on the large sample size, collected 
from all regions in the USA. In addition, the results of this study can be applied to acute 
and ambulatory patients eligible for implantation according to the INTERMACS 
profiling system, regardless of planned device strategy (BTT or DT). 
 The greatest strength of this study is that it is a prospective, randomized trial 
comparing three CF-LVAD models in terms of performance regarding prevention of 
CVA. It will be one of the first trials to specifically analyze data regarding CVA in CF-
LVADs on such a widespread scale.  
Summary 
Patients suffering from refractory, ESHF suffer 1-year mortality rates as high as 
20-50%.6,8 Heart transplantation is the definitive treatment for ESHF. Cardiac transplant 
has been found to improve quality of life and survival compared to established therapies, 
but not every ESHF patient is a likely candidate due to strict eligibility criteria.8 Long-
duration mechanical circulatory assistance, via BTT or DT, can provide cardiac output 
support in patients who are ineligible for or awaiting transplant. Continuous-flow 
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technology has shown significantly improved actuarial survival at 2-year follow-up 
compared to pulsatile LVADs.55 However, CF-LVADs are associated with reduced pulse 
pressure, hemolysis, bleeding and thromboembolic events. Cerebrovascular accidents 
have persisted as one of the major causes for morbidity and mortality in the CF-LVAD 
population. LVADs are associated with endothelial dysfunction and promote a 
procoagulant state. Associated antithrombotic regimens predispose to hemorrhagic 
CVAs. An advanced third-generation CF-LVAD, the HeartMate III, utilizes magnetic 
levitation technology, boasts wider gaps for flow, incorporates biocompatible textured 
materials and has clean fluid dynamics with little evidence for flow stasis. Preliminary 
results from a European study noted a 12% overall incidence of stroke in the HeartMate 
III.69   
This study will provide data supporting or refuting the stroke-free survival 
performance status of an advanced third-generation CF-LVAD in comparison to previous 
LVAD models currently FDA approved for BTT and DT. Evidence from this trial can be 
used to provide information about the relative risk for CVA for each device, and guide 
future research into the efficacy of magnetic levitation technology. 
Clinical and/or public health significance 
MCS mechanisms allow ESHF patients to live fuller lives. CF-LVADs have provided 
similar survival and quality of life outcomes compared to allograft transplant. However, 
stroke remains a leading cause of morbidity in this patient population and limited data 
exists about the long-term morbidity and mortality of stroke in CF-LVADs.5 This study 
aims to provide widely generalizable evidence about a device’s associated incidence and 
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risk of CVA. The results may help to guide treatment paradigms, device assignment and 
future development of technologies that mitigate stroke risk in this high-risk population.  
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APPENDIX I 
Definition of Advanced/End-Stage Heart Failure  
 
1. Severe symptoms of HF with dyspnea, and/or fatigue at rest or with minimal exertion 
(NYHA III or IV) 
 
2. Episodes of fluid retention (pulmonary and/or systemic congestion, peripheral edema) 
and/or of reduced cardiac function output at rest (peripheral hypoperfusion) 
 
3. Objective evidence of severe cardiac dysfunction, shown by at least one of the 
following: 
a) A low LVEF (<30%) 
b) A severe abnormality of cardiac function on Doppler echocardiography with a 
pseudo-normal or restrictive mitral flow pattern 
c) High LV filling pressures (mean PCWP > 16 mmHg and/or mean RAP >12 
mmHg by pulmonary artery catheterization) 
d) High BNP or NT-proBNP plasma levels, in the absence of non-cardiac causes 
 
4. Severe impairment of functional capacity shown by one of the following: 
a) Inability to exercise 
b) 6-MWT distance < 300 meters or less in females or patients greater than or equal 
to 75 years of age  
c) Peak VO2 < 12-14 ml/kg/min 
 
5. History of 1 or more HF hospitalizations within previous 6 months 
 
6. Presence of all of the above listed features despite attempts to optimize therapy with 
diuretics, RAA system inhibitors and beta blockers, unless these interventions are poorly 
tolerated or contraindicated, and CRT, when indicated 
 
HF (heart failure); NYHA (New York Health Association); LVEF (left ventricular 
ejection fraction); PCWP (pulmonary capillary wedge pressure); RAP (right atrial 
pressure); BNP (brain natriuretic peptide); NT (N-terminal); 6-MWT (6-minute walk 
test); VO2 (oxygen consumption); RAA (renin-angiotensin-aldosterone); CRT (cardiac 
resynchronization therapy); Adapted from Kyo, 2014  
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APPENDIX II 
Contraindications for Cardiac Transplantation 
AIDS (acquired immunodeficiency syndrome); HT (heart transplant); SLE (systemic 
lupus erythematosus); FEV1 (forced expiratory volume in 1 second); VAD (ventricular 
assist device); PVD (peripheral vascular disease); BMI (body mass index); Adapted from 
Mancini and Lietz, 2010 
 
 
 
 
Absolute Contraindications 
 Systemic illness with a life expectancy < 2 years despite HT, including: - Active or recent solid organ or blood malignancy within 5 years - AIDS with frequent opportunistic infections - SLE, sarcoid or amyloidosis that has multisystem involvement and is still active - Irreversible renal or hepatic dysfunction in patients considered only for HT - Significant obstructive pulmonary disease (FEV1 < 1 L/min) 
Fixed Pulmonary Hypertension - Pulmonary artery systolic pressure > 60 mm Hg - Mean transpulmonary gradient > 15 mm Hg - Pulmonary vascular resistance > 6 Wood units 
Relative Contraindications 
 Age > 72 years 
Any active infection (except for device-related infection in VAD recipients) 
 Active peptic ulcer disease 
Severe diabetes mellitus with end-organ damage  
Severe peripheral vascular disease or cerebrovascular disease - PVD not amendable to surgical or percutaneous therapy - Symptomatic carotid stenosis - Ankle brachial index < 0.7 - Uncorrected abdominal aortic aneurysm > 6 cm 
Morbid obesity (BMI > 35 kg/m2) or cachexia (BMI < 18 kg/m2) 
Creatinine > 2.5 mg/dL or creatinine clearance < 25 ml/min* 
Bilirubin > 2.5 mg/dL, serum transaminases > 3-times normal, INR > 1.5 off warfarin 
Severe pulmonary dysfunction with FEV1 < 40% normal  
Recent pulmonary infarction within 6 to 8 weeks 
Difficult-to-control hypertension 
Irreversible neurological or neuromuscular disorder 
Active mental illness or psychosocial instability  
Drug, tobacco, or alcohol abuse within 6 months 
Heparin-induced thrombocytopenia within 100 days 
 
*Potentially suitable for HT if inotropic support and hemodynamic management produce a creatinine  
< 2 mg/dL and creatinine clearance > 50 ml/min; combined heart-kidney transplantation may be 
advised  	
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APPENDIX III 
INTERMACS Classifications 
 
Profile Status Description Time-frame for 
Intervention 
1 Critical 
Cardiogenic 
Shock 
Life-threatening hypotension despite 
escalating inotropic support, hypoperfusion, 
worsening acidosis and/or lactate levels 
Definitive therapy 
indicated within hours 
2 Progressive 
Decline 
Declining function despite IV inotropic 
support with worsening renal function, 
nutritional status, volume imbalance; may 
be unable to tolerate inotropes  
Definitive therapy 
indicated within days 
3 Stable, 
Inotrope-
dependent 
Stable blood pressures, organ function, 
nutrition and symptoms on continuous IV 
inotropic support and/or temporary 
circulatory support device for weeks to 
months. Repeated failure to wean from 
support due to hypotension or renal 
dysfunction 
Definitive therapy 
indicated; elective 
intervention within 
weeks to a few months 
4 Resting-
symptoms 
Stabilized close to normal volume status 
with daily symptoms at rest or during ADL; 
diuretic dosing fluctuates; more intensive 
therapy or surveillance should be 
considered; interchange with profile 5  
Definitive therapy 
indicated; elective 
intervention within 
weeks to a few months 
5 Exertion 
Intolerant 
Comfortable at rest and with ADLs; can not 
engage in any other activity; home-bound; 
refractory elevated volume status and renal 
dysfunction may occur, which predisposes 
patient to worsening disease (profile 4 or 
greater). Nutritional and organ function 
may be marginal; may require definitive 
intervention.  
Variable urgency; 
intervention predicated 
on nutritional status, 
organ function and 
activity level 
6 Exertion 
Limited 
No evidence of volume overload, 
comfortable at rest, with ADLs and minor 
activities outside the home. Fatigues with 
minimal, meaningful activity. 
Cardiopulmonary and physiologic testing 
required to confirm severity of cardiac 
dysfunction 
Variable urgency; 
intervention predicated 
on nutritional status, 
organ function and 
activity level 
7 Advanced 
NYHA III 
HF 
Patients without current or recent episodes 
of fluid imbalance, live comfortable with 
meaningful activity, but limited to mild 
exertion.  
Transplant or MCS may 
not be currently 
indicated  
ADL (activities of daily living); IV (intravenous); MCS (mechanical circulatory support); 
Adapted from Kyo, 2014 
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APPENDIX IV 
Lietz-Miller Score for Pre-operative Evaluation/Futile Implant Score 
 
Patient Characteristic Weighted 
Risk Score 
Platelet count <148,000 uL 7 
Serum albumin < 3.3 g/dL 5 
INR > 1.1 4 
Vasodilator therapy  4 
Mean pulmonary arterial pressure < 25 mmHg 3 
Aspartate aminotransferase > 45 U/mL 2 
Hematocrit < 34% 2 
Blood urea nitrogen > 51 U/dL 2 
No intravenous inotropes 2 
Score Interpretation – 1-Year Survival % with LVAD Implant28,73 
Low-risk (0-8) 81.2% 
Medium-risk (9-16) 62.4% 
High-risk (17-19) 27.8% 
Very high-risk (>19) 10.7% 
INR (international normalized ratio); LVAD (left ventricular assist device); Adapted 
from Lietz et al., 2007, Slaughter et al., 2010, Peura et al., 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	58 
APPENDIX V 
Factors Determining Placement of MCS for Bridge Strategy 
CHF (congestive heart failure); RA (right atrial); BiVAD (biventricular assist device); 
RVSWI (right ventricular stroke work index); RVAD (right ventricular assist device); 
Adapted from Mancini and Lietz, 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severity of CHF - INTERMACS profile I-IV - Seattle Heart Failure Model with 1-year mortality > 25% - Heart Failure Survival Score, high-risk group 
 
Feasibility of LVAD Placement - Cardiac anatomy (aortic insufficiency, congenital heart disease, restrictive 
cardiomyopathy, prosthetic valve) - Perioperative Score 
  - Futile Implant Score 
  - Coagulopathic, RA pressures, infection status 
 
Need for BiVAD - RVSWI - University of Michigan RVAD Score 
 
Estimated Wait-list Time for Transplant - Blood type - Sensitization - Weight 
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APPENDIX VI 
Comparison of Adverse Events in Continuous-Flow and Pulsatile LVADs 
 
 
LVAD (left ventricular assist device); RVAD (right ventricular assist device); Adapted 
from Slaughter et al., 2009  
 
 
 
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist
n engl j med 361;23 nejm.org december 3, 2009 2249
with an improved quality of life and functional 
capacity. The survival rate at 2 years among our 
patients with a pulsatile-flow left ventricular assist 
device was similar to that among patients with a 
left ventricular assist device in the REMATCH 
trial,12 whereas the survival rate among our pa-
tients with a continuous-flow device was more than 
twice the rate among the REMATCH patients.
Device durability is an important limitation to 
use of the currently approved pulsatile-flow left 
ventricular assist device as long-term therapy, be-
cause valve or bearing failures occurred routinely 
by 18 months. The need for pump replacement 
in the continuous-flow left ventricular assist de-
vice occurred at a rate of 6 events per 100 patient-
years, almost one eighth the incidence seen with 
the pulsatile-flow device, and was mainly required 
because of damage to the percutaneous lead. There 
were no primary-pump or bearing failures in pa-
tients with a continuous-flow left ventricular as-
sist device, with 62 patients having functioning 
devices for at least 2 years (and 1 patient with 
ongoing device support at 4 years). Redesign of 
the percutaneous lead and development of mod-
ular components may further reduce the infre-
quent need for replacement of the continuous-
flow device.
Concerns persist that left ventricular assist de-
vices may predispose patients to an undue burden 
of thromboembolic and infectious events. The rate 
of ischemic stroke among patients with a contin-
uous-flow left ventricular assist device (6 events 
per 100 patient-years) is similar to that among 
patients with advanced heart failure who do not 
have device support and have other cardiovascu-
lar conditions such as atrial fibrillation.18,19 In our 
study, the rate of bleeding events associated with 
either type of left ventricular assist device were al-
most 10 times the rate of thromboembolic events. 
This finding was also noted in the HeartMate II 
bridge to transplant trial20 and has led many cen-
ters to reduce the targeted international normal-
ized ratio to 1.5 to 2.5 for the continuous-flow left 
ventricular assist device. The smaller pump and 
7 col
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APPENDIX VII 
List of Cardiac Transplant/Mechanical Circulatory Support Centers in the United States 
 
State Center 
Arkansas Baptist Health Medical Center 
 
California Cedars Sinai Medical Center 
 
University of California, San Diego 
 
Sharp Memorial Hospital 
 
Stanford University 
 
Colorado University of Colorado Hospital 
 
Connecticut Yale New Haven Hospital 
 
District of Columbia MedStar Washington Hospital Center 
 
Florida Shands Hospital at University of Florida 
 
Florida Hospital 
 
Tampa General Hospital 
 
Georgia Piedmont Heart Institute 
 
Illinois Northwestern Memorial Hospital 
 
University of Chicago Medical Center 
 
Advocate Christ Medical Center 
 
Indiana IU Health/Methodist Hospital 
 
St. Vincent Hospital 
 
Iowa University of Iowa Hospitals and Clinics 
 
Kentucky Jewish Hospital 
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State Center 
Louisiana Ochsner Medical Center 
 
Massachusetts Brigham & Women’s Hospital 
 
Michigan University of Michigan 
 
Henry Ford Hospital 
 
Spectrum Health Butterworth Hospital 
 
Minnesota University of Minnesota Medical Center 
 
Mayo Clinic Rochester 
 
Missouri Barnes Jewish Hospital 
 
Nebraska University of Nebraska Medical Center 
 
New Jersey Newark Beth Israel Medical Center 
 
New York Montefiore Medical Center 
 
Mt. Sinai Medical Center 
 
Columbia University Medical Center 
 
University of Rochester Medical Center 
 
North Carolina University of North Carolina at Chapel Hill 
 
Carolinas Medical Center 
 
Duke University 
 
Ohio Cleveland Clinic Foundation 
 
Ohio State University Medical Center 
 
Oklahoma INTEGRIS Baptist Medical Center 
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State Center 
Oregon Oregon Health and Science University 
 
Pennsylvania Hershey 
 
Hospital of the University of Pennsylvania 
 
Thomas Jefferson University Hospital 
 
Allegheny General Hospital 
 
South Carolina Medical University of South Carolina 
 
Tennessee Vanderbilt University Medical Center 
 
St. Thomas West Hospital 
 
Texas Baylor Research Institute 
 
Memorial Hermann Health Systems 
 
Methodist Houston 
 
Texas Heart Institute 
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APPENDIX VIII 
CON-FLOW STROKE Inclusion and Exclusion Criteria 		 
NYHA (New York Health Association); LVEF (left ventricular ejection fraction); 
Adapted from Heatley, MS et al., 2016, Aaronson, KD et al., 2012 	
Inclusion Criteria 
1. Subject must be at least 18 years of age at enrollment. 
2. Patient or legally authorized representative has signed the informed consent form. 
3. Body surface area (BSA) greater than or equal to 1.2 m2 
4. NYHA Class III with dyspnea upon mild physical activity or NYHA Class IV, refractory to 
medical management (see item #6) 
5. LVEF less than or equal to 25% 
6. Inotrope dependent or cardiac index < 2.2 L/min/m2 while not on inotropes but meets one of the 
following additional requirements: 
a. On optimal medical management, based on current heart failure practice guidelines for at 
least 45 of the last 60 days but are failing to respond 
b. Advanced heart failure diagnosed for at least 14 days AND dependent on intra-aortic 
balloon pump (IABP) for at least 7 days  
7. Patient meets United Network for Organ Sharing (UNOS) Status 1A or 1B listing criteria, if 
planned device strategy is bridge-to-transplant (BTT).  
 
Exclusion Criteria 
1. Existence of any ongoing mechanical circulatory support other than IABP. 
2. History of previous organ transplant. 
3. History of confirmed, unrepaired abdominal aortic aneurysm > 5 cm. 
4. Cardiothoracic surgery within 30 days of enrollment. 
5. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes, 
diagnostic biomarkers, ongoing pain and hemodynamic abnormalities. 
6. On ventilator support >72 hours within the four days immediately prior to study enrollment. 
7. Pulmonary embolus within three weeks of enrollment, as documented by computed tomography 
scan or nuclear scan. 
8. Pregnancy, confirmed by serum or urine human chorionic gonadotropin (hCG) test if of 
childbearing age.  
9. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the center 
investigator, cardiac surgery, and mechanical circulatory support and transplant team consensus. 
10. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues are likely to 
impair study compliance and LVAD management. 
11. Presence of active, uncontrolled infection. 
12. Intolerance to anticoagulant or antiplatelet therapies or any other peri-/post-operative therapy the 
investigating team will required based on clinical status of the patient. 
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INR (international normalized ratio); FEV1 (forced expiratory volume after 1 second); 
FVC (forced vital capacity); Adapted from Heatley, MS et al., 2016, Aaronson, KD et 
al., 2012 	
Exclusion Criteria Continued: 
13. Presence of any one of the following risk factors for severe end-organ dysfunction/failure: 
a. An INR > 2.0 not due to anticoagulation therapy 
b. Total bilirubin > 43 umol/L (2.5 mg/dl), shock liver or biopsy proven liver cirrhosis 
c. History of chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC < 
0.7, and FEV1 < 50% predicted. 
d. Fixed pulmonary hypertension with a most recent PVR greater than or equal to 8 
Woods unites that is unresponsive to pharmacologic intervention. 
e. History of stroke within 90 days of enrollment or history of severe cerebrovascular 
disease and/or significant, uncorrected carotid stenosis (> 80%)  
f. Serum creatinine > 221 umol/L (2.5 mg/dl) or the need for chronic renal replacement 
therapy 
g. Significant peripheral vascular disease (PVD) accompanied by pain at rest or 
extremity ulceration.  
14. Patient has moderate to severe aortic insufficiency without plans or correction during 
implantation procedure. 
15. Patients with mechanical, animal or human tissue heart valves are excluded. 
16. Pre albumin < 150 mg/L (15 mg/dL) or Albumin < 30g/L (3 g/dL) [if only one value 
available]; Pre albumin < 150 mg/L (15 mg/dL) and Albumin < 30g/L (3 g/dL) [if both 
values available] 
17. Planned biventricular assist device (Bi-VAD) support prior to enrollment. 
18. History of known hypo- or hyper-coagulable states such as disseminated intravascular 
coagulation (DIC) and heparin induced thrombocytopenia (HIT) 
19. Participation in any other clinical investigation that is likely to confound study results 
or affects the study. 
20. Any condition other than HF that could limit survival to less than 24 months.  	
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